Compare options without treating every claim as equal.

D

Lifestyle · NutritionHigh blood pressureStrong evidence

DASH eating pattern

A flexible eating pattern emphasizing fruits, vegetables, whole grains, beans, nuts, fish or poultry, and lower-fat dairy while limiting sodium, sweets, and saturated fat.

View evidence note

Open mechanism, evidence, safety, and connected condition

What it is

DASH stands for Dietary Approaches to Stop Hypertension. It is a food pattern rather than a branded product and can be adapted for culture, budget, preferences, and calorie needs.

Evidence snapshot

Multiple controlled studies and current blood pressure guidance support DASH-style eating for lowering blood pressure. Reduced sodium generally strengthens the effect.

Safety focus

People with kidney disease, potassium restrictions, eating disorders, food insecurity, or major dietary limitations may need an individualized plan rather than generic targets.

Connected condition

High blood pressure overview →

Evidence rating reviewed July 2026. Sources: NHLBI DASH Eating Plan and 2025 AHA/ACC blood pressure guideline summary.

M

Lifestyle · MovementBlood pressure & diabetesStrong evidence

Structured physical activity

Planned aerobic, resistance, mobility, or mixed activity matched to current ability, goals, safety needs, and access.

View evidence note

Open mechanism, evidence, safety, and connected condition

What it is

Physical activity includes intentional exercise and everyday movement. A useful plan is specific, progressive, realistic, and flexible enough to continue over time.

Evidence snapshot

Regular activity is a core evidence-based component of blood pressure and type 2 diabetes management, with benefits that extend to cardiovascular fitness, function, and well-being.

Safety focus

New chest pain, fainting, severe shortness of breath, unstable medical conditions, or major mobility limitations warrant professional guidance before increasing intensity.

Connected condition

High blood pressure →
Type 2 diabetes →

Evidence rating reviewed July 2026. Sources: American Heart Association and CDC diabetes activity guidance.

CBT

Behavioral treatment · Psychotherapy3 prominent indications

Cognitive behavioral therapy

A structured, skills-based psychotherapy. The techniques and treatment protocol differ by condition, so evidence is rated separately for each indication.

Chronic insomnia (CBT-I)Strong evidence Changes sleep-related behaviors and thought patterns while strengthening the sleep system. View evidence note

What it is

CBT-I commonly combines stimulus control, sleep scheduling or restriction, cognitive strategies, relaxation, and education. It can be delivered in person, by telehealth, or through validated digital programs.

Evidence snapshot

ACP recommends CBT-I as first-line treatment for adults with chronic insomnia. Benefits can persist after active treatment because patients learn reusable skills.

Safety focus

Temporary sleepiness can occur during sleep-restriction components. People with certain conditions or high safety-sensitive demands may need clinician-guided modification.

Connected condition

Chronic insomnia overview →

Evidence rating reviewed July 2026. Source: American College of Physicians clinical practice guideline.

Generalized anxiety disorderStrong evidence Builds skills for changing patterns of worry, avoidance, attention, and behavior. View evidence note

What it is

CBT for GAD may include education, monitoring, cognitive restructuring, exposure to uncertainty or avoided situations, problem-solving, relaxation skills, and between-session practice.

Evidence snapshot

NIMH describes CBT as well studied and the gold-standard psychotherapy for GAD. It can be used alone or with medication based on severity, access, preference, and prior response.

Safety focus

Working with feared thoughts or situations can temporarily increase distress. Treatment should be paced collaboratively, and urgent safety concerns, mania, psychosis, or severe depression need appropriate clinical care.

Connected condition

Generalized anxiety disorder overview →

Evidence rating reviewed July 2026. Source: NIMH generalized anxiety disorder guide.

DepressionStrong evidence Changes unhelpful thought and behavior patterns while building practical coping and activation skills. View evidence note

What it is

CBT for depression commonly uses behavioral activation, problem-solving, structured monitoring, and skills for identifying and changing unhelpful thinking patterns.

Evidence snapshot

CBT is an evidence-based depression treatment and can be used alone for some milder presentations or alongside medication, depending on severity, preference, access, and prior response.

Safety focus

Worsening hopelessness, inability to function, psychosis, mania, or thoughts of self-harm require prompt clinical assessment. Therapy should be delivered by a qualified professional and tailored to the person.

Connected condition

Depression overview →

Evidence rating reviewed August 2026. Source: NIMH depression guide.

Rx

Prescription medication · ACE inhibitor3 prominent indications

ACE inhibitors

A medicine class that includes lisinopril, enalapril, and ramipril. ACE inhibitors reduce angiotensin II signaling, with different goals and outcome evidence across blood pressure, heart failure, and kidney disease.

High blood pressureStrong evidence Relaxes blood vessels and reduces sodium-retaining signals to lower blood pressure. View evidence note

What it is

ACE inhibitors block angiotensin-converting enzyme, reducing signals that tighten blood vessels and retain sodium. Dose selection depends on blood pressure, kidney function, potassium, tolerability, and other medicines.

Evidence snapshot

ACE inhibitors are established blood pressure-lowering therapies with extensive clinical use and guideline support for appropriate patients. The rating applies to blood pressure lowering—not suitability for every person.

Safety focus

Cough, dizziness, kidney-function changes, high potassium, rare angioedema, interactions, and serious fetal harm during pregnancy require attention.

Connected condition

High blood pressure overview →

Evidence rating reviewed July 2026. Sources: 2025 AHA/ACC guideline summary and FDA lisinopril prescribing information.

Heart failure with reduced ejection fractionStrong evidence Reduces mortality and hospitalization when ARNI therapy is not feasible. View evidence note

What it is

ACE inhibitors reduce harmful renin–angiotensin signaling, vascular resistance, and cardiac remodeling. They are used in HFrEF when an angiotensin receptor–neprilysin inhibitor is not feasible.

Evidence snapshot

Longstanding trial and guideline evidence supports ACE inhibitors for reducing illness and death in symptomatic HFrEF. They must not overlap with ARNI therapy, and switching requires a washout interval.

Safety focus

Blood pressure, kidney function, and potassium need monitoring. Cough or angioedema may require a different drug class; pregnancy is contraindicated.

Connected condition

Heart failure overview →

Evidence rating reviewed August 2026. Sources: 2022 AHA/ACC/HFSA heart failure guideline summary and FDA lisinopril prescribing information.

Chronic kidney disease with albuminuriaStrong evidence Lowers albuminuria and slows progression in recommended CKD groups. View evidence note

What it is

ACE inhibitors reduce pressure within the kidney’s filtering units as well as systemic blood pressure. Kidney benefit is most clearly established for CKD with moderately or severely increased albuminuria.

Evidence snapshot

KDIGO recommends renin–angiotensin system inhibition with an ACE inhibitor or ARB for defined albuminuric CKD groups. The indication depends on albuminuria, diabetes status, blood pressure, potassium, and kidney function.

Safety focus

Creatinine and potassium should be checked after starting or increasing treatment. A modest early creatinine rise may be expected, while a larger rise, severe low blood pressure, or high potassium requires reassessment.

Connected condition

Chronic kidney disease overview →

Evidence rating reviewed August 2026. Source: KDIGO 2024 CKD guideline.

Rx

Prescription medication · Statin3 prominent indications

Statins

Atorvastatin, rosuvastatin, and related medicines lower LDL cholesterol. Treatment intensity and expected benefit differ across primary and secondary cardiovascular prevention.

Hyperlipidemia and primary preventionStrong evidenceLowers LDL and prevents first cardiovascular events in appropriate risk groups.View evidence note

What it is

Statins reduce liver cholesterol production and increase LDL removal. Choice and intensity reflect lipid levels, overall risk, goals, interactions, and preferences.

Evidence snapshot

Statins are foundational lipid-lowering therapy; absolute preventive benefit increases with baseline cardiovascular risk.

Safety focus

Muscle symptoms and interactions need review; serious muscle or liver injury is rare. Pregnancy and breastfeeding require individualized guidance.

Connected condition

Hyperlipidemia overview →

Evidence rating reviewed August 2026. Source: 2026 ACC/AHA dyslipidemia guidance.

Coronary artery diseaseStrong evidenceReduces recurrent heart attack and other atherosclerotic events.View evidence note

What it is

High-intensity or maximally tolerated statin therapy is commonly used after heart attack, angina, plaque diagnosis, stenting, or bypass surgery.

Evidence snapshot

Statins are first-line secondary-prevention therapy in chronic coronary disease and lower cardiovascular events and mortality.

Safety focus

Symptoms and interactions should be addressed without casually abandoning therapy; dose changes or nonstatin additions can preserve protection.

Connected condition

Coronary artery disease overview →

Evidence rating reviewed August 2026. Source: 2023 chronic coronary disease guideline.

Secondary prevention after ischemic stroke or TIAStrong evidenceLowers recurrent stroke and cardiovascular risk when atherosclerotic prevention is indicated.View evidence note

What it is

Statin intensity and LDL goals depend on stroke cause, atherosclerosis, age, tolerability, and other vascular disease.

Evidence snapshot

Secondary stroke-prevention guidance strongly supports lipid lowering with statins for appropriate ischemic stroke and TIA survivors.

Safety focus

Hemorrhagic stroke history and individual competing risks require specialist context; do not stop therapy without review.

Connected condition

Stroke and TIA overview →

Evidence rating reviewed August 2026. Source: AHA/ASA secondary stroke-prevention guideline.

Rx

Prescription medication · Biguanide2 prominent indications

Metformin

A well-established medicine that reduces liver glucose production and improves insulin sensitivity. Expected benefit differs between diabetes treatment and diabetes prevention.

Type 2 diabetesStrong evidenceLowers glucose with extensive efficacy, safety, and cost experience.View evidence note

What it is

A common initial or combination medicine selected around glucose needs, heart and kidney conditions, weight goals, cost, and preference.

Evidence snapshot

Metformin has extensive evidence for glucose lowering in appropriate people with type 2 diabetes.

Safety focus

Gastrointestinal effects are common. Kidney function, vitamin B12, acute illness, and rare lactic acidosis risk require monitoring.

Connected condition

Type 2 diabetes overview →

Evidence rating reviewed August 2026. Source: ADA 2026 Standards of Care.

Diabetes prevention in selected high-risk adultsStrong evidenceDelays progression from prediabetes to type 2 diabetes in groups likely to benefit.View evidence note

What it is

Metformin may be considered for higher-risk prediabetes, such as younger adults with greater adiposity, prior gestational diabetes, or rising A1C despite lifestyle efforts.

Evidence snapshot

The Diabetes Prevention Program showed durable risk reduction, although intensive lifestyle intervention was more effective overall.

Safety focus

The same kidney, gastrointestinal, B12, and acute-illness precautions apply. Prediabetes alone does not automatically require medication.

Connected condition

Prediabetes overview →

Evidence rating reviewed August 2026. Source: ADA 2026 Standards of Care.

N

Natural product · Hormone supplementChronic insomniaLimited / mixed

Melatonin

A hormone involved in circadian timing and a widely sold supplement. Evidence differs substantially by sleep problem, dose, formulation, and measured outcome.

View evidence note

Open mechanism, evidence, safety, and connected condition

What it is

Melatonin signals biological night; it is not simply a general sedative. Evidence for jet lag or certain circadian-timing problems should not be assumed to apply to all chronic insomnia.

Evidence snapshot

Research suggests modest improvement in some outcomes such as time to fall asleep, while sleep quality or time awake may not improve consistently. Product and study variability reduce certainty.

Safety focus

Possible drowsiness, headache, interactions, product-quality variation, and uncertainty about long-term use matter. Children, pregnancy, and people using anticoagulants or sedatives need professional input.

Connected condition

Chronic insomnia overview →

Evidence rating reviewed July 2026. Source: NCCIH sleep disorders and complementary approaches.

Mg

Natural product · Mineral supplementHigh blood pressureLimited / mixed

Magnesium

An essential mineral found in many foods and supplements. Adequate intake matters for health, but supplementation is not equivalent to an established blood pressure treatment.

View evidence note

Open mechanism, evidence, safety, and connected condition

What it is

Magnesium participates in muscle, nerve, glucose, and blood pressure regulation. A deficiency indication is different from using a supplement to treat hypertension.

Evidence snapshot

Clinical trials suggest magnesium supplements lower blood pressure only marginally on average. More research is needed to understand who, if anyone, receives a clinically meaningful benefit.

Safety focus

Supplements can cause diarrhea and may interact with antibiotics or other medicines. Reduced kidney function increases the risk of magnesium accumulation.

Connected condition

High blood pressure overview →

Evidence rating reviewed July 2026. Source: NIH Office of Dietary Supplements magnesium fact sheet.

V

Natural product · Herbal supplementChronic insomniaLimited / mixed

Valerian

An herbal product marketed for sleep and relaxation. Preparations vary, and the evidence for chronic insomnia is inconsistent.

View evidence note

Open mechanism, evidence, safety, and connected condition

What it is

Valerian products may differ by species, plant part, extraction, dose, and combination ingredients, which makes both research comparison and real-world product selection difficult.

Evidence snapshot

Overall evidence for sleep benefit is inconsistent. Limited or mixed evidence should not be interpreted as proof that a product is harmless or as a reason to delay effective care.

Safety focus

Drowsiness and interactions with alcohol, sedatives, or other products are important concerns. Avoid activities requiring alertness until effects are known.

Connected condition

Chronic insomnia overview →

Evidence rating reviewed July 2026. Source: NCCIH valerian review.

Rx

Prescription medication · TriptanMigraineStrong evidence

Triptans

A migraine-specific prescription medicine class that includes sumatriptan, rizatriptan, and zolmitriptan. Triptans are used to stop an attack after it begins, not as daily prevention.

View evidence note

Open mechanism, evidence, safety, and connected condition

What it is

Triptans activate serotonin 5-HT1B/1D receptors involved in migraine pathways. Products differ in onset, duration, formulation, and interaction profile; oral, nasal, and injectable options can help match the attack pattern and whether nausea or vomiting is present.

Evidence snapshot

High-strength evidence shows triptans improve two-hour and sustained pain outcomes compared with placebo for acute episodic migraine. They are commonly used for moderate or severe attacks or attacks that do not respond adequately to nonopioid pain relievers.

Safety focus

Triptans are not appropriate with certain heart, blood-vessel, or stroke conditions, uncontrolled high blood pressure, or some interacting migraine medicines. A prescriber should review pregnancy, other serotonergic medicines, and new chest or neurological symptoms. Frequent acute-medicine use can contribute to medication-overuse headache.

Connected condition

Migraine overview →

Evidence rating reviewed July 2026. Sources: NINDS migraine overview, AHRQ acute migraine evidence review, and American Headache Society guidance library.

PPI

OTC & prescription medication · PPIGERDStrong evidence

Proton pump inhibitors

An acid-suppressing medicine class that includes omeprazole, esomeprazole, lansoprazole, and pantoprazole. Some products are sold over the counter and others by prescription.

View evidence note

Open mechanism, evidence, safety, and connected condition

What it is

PPIs block the final step of acid secretion by proton pumps in the stomach lining. Product, timing, dose, and course depend on the indication; taking a PPI correctly can matter as much as switching products or increasing the dose.

Evidence snapshot

PPIs are more effective than H2-receptor blockers for healing reflux-related esophageal injury and are a first-line medicine option for typical troublesome GERD symptoms. People who respond should generally use the lowest effective dose and have the continuing indication reviewed.

Safety focus

Headache, diarrhea, nausea, abdominal discomfort, or constipation can occur. Long-term or high-dose use deserves periodic review for indication, interactions, and individual risks; an association with intestinal C. difficile infection is recognized. Alarm symptoms require assessment rather than prolonged self-treatment.

Connected condition

GERD overview →

Evidence rating reviewed July 2026. Sources: NIDDK GERD treatment overview, AGA personalized GERD guidance, and ACG acid reflux overview.

ICS

Prescription medication · Inhaled corticosteroidAsthmaStrong evidence

Inhaled corticosteroid–containing therapy

Anti-inflammatory inhaler treatment using a corticosteroid alone or in a combination inhaler. Examples of inhaled corticosteroids include budesonide, fluticasone, and beclomethasone.

View evidence note

Open mechanism, evidence, safety, and connected condition

What it is

Inhaled corticosteroids reduce inflammation and airway sensitivity. They may be prescribed daily, in an ICS-formoterol maintenance-and-reliever plan, or in another age- and severity-specific regimen. Not every combination inhaler can be used for quick relief.

Evidence snapshot

Current international guidance recommends ICS-containing treatment for people with asthma because it substantially reduces severe flare-ups, hospitalizations, and asthma deaths. The specific device and schedule should be individualized and paired with technique checks.

Safety focus

Hoarseness and oral thrush are common local effects; correct technique, a spacer when appropriate, and rinsing and spitting after use can reduce risk. Dose and growth should be monitored in children. Follow the written action plan and do not substitute one inhaler’s role for another.

Connected condition

Asthma overview →

Evidence rating reviewed July 2026. Sources: GINA 2026 Summary Guide, NHLBI treatment and action plan, and NHLBI focused asthma guideline FAQs.

NSAID

Topical medication · NSAIDOsteoarthritisStrong evidence

Topical NSAIDs

Anti-inflammatory medicine applied over a painful joint. Diclofenac gel or solution is the most common U.S. example, with some formulations sold over the counter.

View evidence note

Open mechanism, evidence, safety, and connected condition

What it is

Topical nonsteroidal anti-inflammatory drugs reduce prostaglandin production near the application site. They generally produce less whole-body exposure than oral NSAIDs, but the labeled amount, schedule, body site, and measuring instructions still matter.

Evidence snapshot

The ACR/Arthritis Foundation guideline strongly recommends topical NSAIDs for knee osteoarthritis and conditionally recommends them for hand osteoarthritis. Evidence should not be generalized to deep joints such as the hip, where topical medicine is unlikely to reach the joint adequately.

Safety focus

Skin irritation can occur. Despite lower systemic exposure, diclofenac retains NSAID warnings involving cardiovascular events, stomach or intestinal bleeding, kidney effects, allergy, and pregnancy. Do not apply to damaged skin or combine with oral NSAIDs unless a clinician or pharmacist confirms the plan.

Connected condition

Osteoarthritis overview →

Evidence rating reviewed July 2026. Sources: 2019 ACR/Arthritis Foundation osteoarthritis guideline, NIAMS osteoarthritis treatment guide, and FDA diclofenac topical prescribing information.

SSRI

Prescription medication · SSRI/SNRI2 prominent indications

SSRIs and SNRIs

Antidepressant classes that alter serotonin signaling, with SNRIs also affecting norepinephrine. Specific medicines, approved uses, evidence, and safety considerations differ by indication.

Major depressionStrong evidence Reduces depressive symptoms for many adults with moderate-to-severe major depression. View evidence note

What it is

SSRIs reduce serotonin reuptake; SNRIs reduce serotonin and norepinephrine reuptake. Medicines within each class differ in approved uses, half-life, interactions, side effects, and discontinuation effects.

Evidence snapshot

Second-generation antidepressants, including SSRIs and SNRIs, are guideline-recommended initial options for adults with moderate-to-severe major depression. No single medicine is best for everyone.

Safety focus

Nausea, sleep changes, sexual effects, agitation, bleeding risk, low sodium, and withdrawal-like symptoms can occur. Monitor for worsening depression or suicidal thinking and assess for bipolar disorder, serotonin syndrome risks, pregnancy, and interactions.

Connected condition

Depression overview →

Evidence rating reviewed July 2026. Sources: ACP major depression guideline and NIMH depression overview.

Generalized anxiety disorderStrong evidence Reduces persistent anxiety; benefit usually develops over several weeks. View evidence note

What it is

Examples used for GAD include the SSRI escitalopram and the SNRIs duloxetine and venlafaxine. Selection depends on symptoms, interactions, prior response, side effects, and coexisting conditions.

Evidence snapshot

SSRIs and SNRIs are established medication options for GAD. They can be combined with psychotherapy and are generally preferred over long-term benzodiazepine treatment.

Safety focus

Early nausea, sleep change, headache, agitation, sexual effects, bleeding risk, low sodium, and discontinuation symptoms can occur. Monitor worsening mood or suicidal thoughts, especially early in treatment.

Connected condition

Generalized anxiety disorder overview →

Evidence rating reviewed July 2026. Sources: NIMH generalized anxiety disorder guide and FDA duloxetine prescribing information.

SGLT2

Prescription medication · SGLT2 inhibitor3 prominent indications

SGLT2 inhibitors

A medicine class that includes dapagliflozin, empagliflozin, and canagliflozin. Certain agents protect the kidneys and heart in eligible people, including some without diabetes.

Chronic kidney diseaseStrong evidence Slows kidney-disease progression and lowers cardiorenal risk in defined CKD groups. View evidence note

What it is

SGLT2 inhibitors change sodium and glucose handling in the kidney, reducing pressure within the kidney’s filtering units. Kidney protection can extend beyond glucose lowering and to eligible people without diabetes.

Evidence snapshot

KDIGO strongly recommends SGLT2 inhibitors for defined CKD groups, including type 2 diabetes with CKD and suitable kidney function, CKD with higher albuminuria, or heart failure. Benefit and labeling vary by medicine and eGFR.

Safety focus

Genital yeast infections, increased urination, dehydration, low blood pressure, and an early reversible eGFR dip can occur. Ketoacidosis is rare but serious; sick-day, fasting, and perioperative instructions matter.

Connected condition

Chronic kidney disease overview →

Evidence rating reviewed July 2026. Sources: KDIGO 2024 CKD guideline and KDIGO CKD key takeaways.

Type 2 diabetesStrong evidence Lowers glucose while offering cardiorenal benefits for selected patients. View evidence note

What it is

SGLT2 inhibitors lower blood glucose by increasing urinary glucose excretion. Their place in diabetes care depends on glucose needs, heart or kidney disease, eGFR, adverse effects, cost, and the specific agent’s labeling.

Evidence snapshot

Diabetes standards support SGLT2 inhibitors as effective glucose-lowering therapy and prioritize them for many people with heart failure, chronic kidney disease, or high cardiovascular risk because benefits extend beyond A1C reduction.

Safety focus

Genital infections, dehydration, low blood pressure, and rare ketoacidosis require prevention guidance. Insulin or sulfonylurea doses may need review to reduce hypoglycemia risk when therapies are combined.

Connected condition

Type 2 diabetes overview →

Evidence rating reviewed August 2026. Sources: American Diabetes Association Standards of Care in Diabetes—2026 and FDA dapagliflozin safety overview.

Heart failureStrong evidence Reduces heart-failure hospitalization across a broad range of ejection fractions. View evidence note

What it is

Selected SGLT2 inhibitors are heart-failure medicines even when a patient does not have diabetes. Their effects involve kidney sodium handling, fluid balance, and cardiac and metabolic pathways.

Evidence snapshot

SGLT2 inhibitors are foundational treatment for HFrEF and are also guideline-supported in heart failure with mildly reduced or preserved ejection fraction. Benefits include fewer heart-failure hospitalizations.

Safety focus

Volume status, kidney function, blood pressure, genital infections, and ketoacidosis precautions need review. Diuretic doses may need reassessment if dizziness, dehydration, or low blood pressure develops.

Connected condition

Heart failure overview →

Evidence rating reviewed August 2026. Sources: 2022 AHA/ACC/HFSA heart failure guideline summary and AHA heart-failure medication guide.

TCS

Topical medication · CorticosteroidAtopic dermatitisStrong evidence

Topical corticosteroids

Anti-inflammatory creams, ointments, lotions, solutions, or foams ranging from low to very high potency. Hydrocortisone and triamcinolone are familiar examples.

View evidence note

Open mechanism, evidence, safety, and connected condition

What it is

Topical corticosteroids suppress inflammatory signals in the skin. Selection depends on potency, vehicle, body site, age, flare severity, skin thickness, and planned duration; a low-potency product and a super-potent product are not interchangeable.

Evidence snapshot

AAD guidelines strongly recommend topical corticosteroids for atopic dermatitis. They are established first-line treatment for inflammatory flares and are usually used alongside regular moisturizers and trigger-aware skin care.

Safety focus

Correct intermittent use is generally effective and well tolerated. Excessive potency, amount, duration, or occlusion can cause skin thinning, stretch marks, color change, or systemic absorption. The face, eyelids, skin folds, genitals, and young children require extra care; infection may need separate treatment.

Connected condition

Atopic dermatitis overview →

Evidence rating reviewed July 2026. Sources: AAD atopic dermatitis guidelines, AAD topical therapy guideline summary, AAD topical corticosteroid safety guide, and NIAMS treatment guide.

LAMA

Prescription inhaler · LAMA/LABACOPDStrong evidence

Long-acting inhaled bronchodilators

LAMA and LABA medicines relax airway smooth muscle for sustained symptom control. They may be used alone or together, depending on symptoms and exacerbation risk.

View evidence note

Open mechanism, evidence, safety, and connected condition

What it is

Long-acting muscarinic antagonists such as tiotropium and long-acting beta2-agonists such as formoterol reduce bronchoconstriction through different pathways. Device choice, technique, dosing schedule, dexterity, cost, and response all matter.

Evidence snapshot

GOLD recommends long-acting bronchodilator therapy as a foundation of symptomatic COPD treatment. Dual LAMA/LABA therapy can improve breathing and reduce exacerbations more than one bronchodilator for selected patients.

Safety focus

Possible effects include dry mouth, urinary retention, tremor, palpitations, or eye symptoms if mist contacts the eyes. Inhaled corticosteroids have a separate role and are added for selected exacerbation-prone patients rather than used alone for COPD.

Connected condition

COPD overview →

Evidence rating reviewed July 2026. Source: GOLD 2026 Report and Pocket Guide.

PR

Lifestyle · RehabilitationCOPDStrong evidence

Pulmonary rehabilitation

A structured program combining supervised exercise, education, breathing and energy-conservation strategies, and support for self-management.

View evidence note

Open mechanism, evidence, safety, and connected condition

What it is

Programs are tailored after assessment and commonly include aerobic and strength training, symptom-management skills, inhaler education, and planning for long-term activity. They can be especially valuable after a COPD hospitalization.

Evidence snapshot

Pulmonary rehabilitation improves shortness of breath, exercise capacity, and health-related quality of life across COPD severity levels, with particularly strong evidence in moderate-to-severe disease.

Safety focus

Exercise intensity and oxygen use should be individualized. New chest pain, fainting, severe breathlessness, or unsafe oxygen levels during activity require immediate review by the rehabilitation team.

Connected condition

COPD overview →

Evidence rating reviewed July 2026. Sources: GOLD 2026 Report and NHLBI pulmonary rehabilitation overview.

Fiber

Nutrition · Soluble fiber3 prominent indications

Soluble fiber

Gel-forming fiber—most commonly psyllium—used for bowel symptoms and as a modest cholesterol-lowering adjunct. Product, dose, and outcome differ by indication.

Irritable bowel syndromeStrong evidence Helps regulate stool form and improve overall IBS symptoms. View evidence note

What it is

Soluble fiber absorbs water and forms a gel, which can soften hard stool or add form to loose stool. Psyllium has better support than coarse, poorly soluble wheat bran.

Evidence snapshot

AGA guidance identifies soluble fiber as efficacious for global IBS symptoms. Benefit depends on product, dose, adherence, and individual tolerance.

Safety focus

Start low and increase gradually because gas, bloating, or cramping may occur. Take with adequate fluid and separate from medicines when directed.

Connected condition

Irritable bowel syndrome overview →

Evidence rating reviewed July 2026. Sources: AGA diet guidance and NIDDK IBS treatment guide.

Occasional constipationStrong evidence Acts as a bulk-forming laxative to soften stool and support regularity. View evidence note

What it is

Psyllium absorbs liquid and increases stool bulk, helping bowel movements pass more regularly. Effects are not immediate and typically develop over 12 to 72 hours.

Evidence snapshot

Fiber is a standard first self-care step for constipation, and psyllium products are labeled as bulk-forming laxatives for occasional constipation.

Safety focus

Adequate liquid is essential because dry psyllium can swell and cause choking or blockage. Swallowing difficulty, severe pain, vomiting, bleeding, or a sudden bowel-habit change needs clinical assessment.

Connected condition

Chronic constipation overview →

Evidence rating reviewed August 2026. Sources: NIDDK constipation treatment guide and DailyMed psyllium label.

Elevated LDL cholesterolModerate evidence Produces a modest LDL reduction as an adjunct to a heart-healthy eating pattern. View evidence note

What it is

Viscous soluble fiber increases bile-acid excretion and can modestly lower LDL cholesterol. Psyllium complements rather than replaces indicated lipid-lowering medication.

Evidence snapshot

Randomized-trial meta-analyses show modest reductions in LDL and non-HDL cholesterol with psyllium. Evidence is consistent for the lipid outcome, but the expected effect is smaller than with statin therapy.

Safety focus

Choose products with attention to added sugar and sodium. Adequate fluid and spacing from oral medicines are important; treatment decisions should follow overall cardiovascular risk, not LDL alone.

Connected condition

Hyperlipidemia overview →

Evidence rating reviewed August 2026. Sources: Systematic review of psyllium and lipid outcomes and FDA food-labeling guide.

FOD

Lifestyle · NutritionIrritable bowel syndromeStrong evidence

Structured low-FODMAP diet trial

A three-phase nutrition intervention that briefly reduces fermentable carbohydrates, then reintroduces them to identify a personalized, minimally restrictive pattern.

View evidence note

Open mechanism, evidence, safety, and connected condition

What it is

FODMAPs are fermentable carbohydrates that can increase fluid and gas in the bowel. The intervention includes restriction for no more than about four to six weeks, structured reintroduction, and long-term personalization.

Evidence snapshot

AGA identifies the low-FODMAP diet as the most evidence-based diet intervention for IBS. It helps a subset of patients and should be stopped if a defined trial produces no meaningful response.

Safety focus

Long-term blanket restriction can reduce dietary variety and nutritional adequacy and may worsen disordered eating. A gastrointestinal dietitian is especially important for people at risk of malnutrition, food insecurity, or an eating disorder.

Connected condition

Irritable bowel syndrome overview →

Evidence rating reviewed July 2026. Source: AGA clinical guidance on diet in IBS.

T4

Prescription medication · Thyroid hormoneHypothyroidismStrong evidence

Levothyroxine

Synthetic thyroxine (T4), biologically equivalent to the main hormone made by a healthy thyroid and the standard replacement treatment for hypothyroidism.

View evidence note

Open mechanism, evidence, safety, and connected condition

What it is

Levothyroxine replaces missing T4, which tissues convert to active T3 as needed. Dose depends on body size, age, pregnancy, heart health, remaining thyroid function, absorption, and the cause of hypothyroidism.

Evidence snapshot

Levothyroxine is the standard of care and successfully controls overt primary hypothyroidism for most patients. Laboratory monitoring guides adjustment; symptoms alone cannot establish whether a dose is correct.

Safety focus

Too much can cause palpitations, atrial fibrillation, bone loss, anxiety, or heat intolerance; too little leaves hypothyroidism undertreated. Take consistently and separate from iron, calcium, and other interfering products as instructed.

Connected condition

Hypothyroidism overview →

Evidence rating reviewed July 2026. Sources: NIDDK hypothyroidism guide and American Thyroid Association treatment guide.

T4+T3

Prescription medication · Combination hormoneHypothyroidismLimited / mixed

Combination T4/T3 therapy

Levothyroxine combined with liothyronine (T3), sometimes considered for selected patients with persistent symptoms despite optimized standard therapy.

View evidence note

Open mechanism, evidence, safety, and connected condition

What it is

Liothyronine supplies active T3 directly and has a shorter half-life than T4, producing larger peaks and troughs. Combination treatment is not the same as desiccated thyroid extract and requires precise dosing and monitoring.

Evidence snapshot

Clinical trials have not demonstrated consistent superiority over levothyroxine alone. Expert consensus supports better research and allows a carefully defined specialist-guided trial only in selected patients after other explanations for symptoms are reviewed.

Safety focus

Excess T3 can cause palpitations, arrhythmia, anxiety, and bone loss. It requires caution in heart disease and is not routine therapy during pregnancy. Stop or adjust only with the prescribing clinician.

Connected condition

Hypothyroidism overview →

Evidence rating reviewed July 2026. Sources: ATA/BTA/ETA consensus summary and ATA treatment guideline summary.

DOAC

Prescription medication · Anticoagulant2 prominent indications

Direct oral anticoagulants

Apixaban, dabigatran, edoxaban, and rivaroxaban inhibit specific clotting factors. The medicine, dose, starting regimen, and duration differ substantially by indication.

Atrial fibrillation stroke preventionStrong evidence Reduces stroke and systemic embolism when estimated AF-related risk warrants anticoagulation. View evidence note

What it is

DOACs inhibit factor Xa or thrombin and do not require routine INR monitoring. AF dosing depends on the medicine, kidney and liver function, age, weight, and interactions.

Evidence snapshot

When stroke risk warrants anticoagulation, the ACC/AHA guideline prefers DOACs over warfarin except with mechanical heart valves or moderate-to-severe mitral stenosis. Aspirin is not an equivalent substitute.

Safety focus

Bleeding is the central risk. Missed doses and unplanned interruption can quickly reduce protection; procedures require a specific plan. Severe bleeding, major head trauma, or stroke symptoms need urgent care.

Connected condition

Atrial fibrillation overview →

Evidence rating reviewed July 2026. Sources: 2023 ACC/AHA/ACCP/HRS guideline key perspectives and AHA medication overview.

Deep-vein thrombosis and pulmonary embolismStrong evidence Treats acute VTE and lowers the risk of recurrent DVT or PE. View evidence note

What it is

Selected DOACs treat DVT and PE and can continue as secondary prevention. Initial dose, need for several days of injectable anticoagulation, and later dose reduction vary by medicine.

Evidence snapshot

Current guidance recommends DOACs over vitamin K antagonists for many eligible patients with acute DVT or PE. Duration is individualized around the clot’s setting, recurrence risk, bleeding risk, and patient preferences.

Safety focus

Active bleeding, severe kidney or liver disease, pregnancy, antiphospholipid syndrome, cancer context, drug interactions, and adherence can change the safest option. New chest pain, severe shortness of breath, coughing blood, or one-sided leg swelling needs urgent assessment.

Connected condition

Venous thromboembolism overview →

Evidence rating reviewed August 2026. Sources: 2026 AHA/ACC pulmonary embolism guideline summary and FDA apixaban prescribing information.

β

Prescription medication · Beta blocker3 prominent indications

Beta blockers

A medicine class that reduces the effects of adrenaline on the heart and circulation. The specific beta blocker matters: agents, doses, outcomes, and evidence differ by indication.

Atrial fibrillation rate controlStrong evidence Slows AV-node conduction to control a rapid ventricular rate and related symptoms. View evidence note

What it is

Beta blockers slow conduction through the heart’s AV node. They control rate rather than reliably restoring normal rhythm, and dose goals depend on symptoms, activity, blood pressure, heart function, and other medicines.

Evidence snapshot

Guidelines support beta blockers as an initial rate-control option for many patients with atrial fibrillation. Diltiazem, verapamil, or digoxin may be more appropriate in some clinical situations.

Safety focus

Slow pulse, low blood pressure, fatigue, dizziness, and worsening of some breathing symptoms can occur. Selection requires care with conduction disease, asthma or COPD, decompensated heart failure, and other heart-rate-lowering medicines.

Connected condition

Atrial fibrillation overview →

Evidence rating reviewed July 2026. Sources: 2023 ACC/AHA/ACCP/HRS atrial fibrillation guideline and AHA medication overview.

High blood pressureStrong evidence Lowers heart rate, cardiac output, and renin signaling to reduce blood pressure. View evidence note

What it is

Several beta blockers lower blood pressure. They are especially useful when another reason for beta blockade is present, such as angina, a prior heart attack, certain arrhythmias, or heart failure.

Evidence snapshot

Beta blockers reliably lower blood pressure and remain established antihypertensive medicines. For uncomplicated hypertension, current guidelines generally prioritize other first-line classes because outcome evidence and tolerability differ.

Safety focus

Heart rate, blood pressure, dizziness, fatigue, sexual effects, breathing disease, and interactions guide selection. Abrupt withdrawal can provoke rebound fast heart rate, high blood pressure, angina, or heart attack.

Connected condition

High blood pressure overview →

Evidence rating reviewed August 2026. Sources: 2025 AHA/ACC high blood pressure guideline summary, AHA cardiac medication guide, and FDA metoprolol succinate prescribing information.

Heart failure with reduced ejection fractionStrong evidence Selected agents improve survival and reduce hospitalization in stable HFrEF. View evidence note

What it is

Evidence-based HFrEF beta blockers are carvedilol, metoprolol succinate, and bisoprolol. Treatment is usually started at a low dose in stable patients and increased gradually as tolerated.

Evidence snapshot

These specific beta blockers are a foundation of guideline-directed HFrEF therapy, with strong evidence for reducing death and heart-failure hospitalization. The benefit should not be generalized to every beta blocker.

Safety focus

Starting or increasing treatment during decompensated heart failure requires clinical judgment. Worsening fluid retention, very slow pulse, low blood pressure, dizziness, or fainting needs prompt review; treatment should not be stopped suddenly without guidance.

Connected condition

Heart failure overview →

Evidence rating reviewed August 2026. Sources: 2022 AHA/ACC/HFSA heart failure guideline summary, AHA heart-failure medication guide, and FDA metoprolol succinate prescribing information.

BP

Prescription medication · BisphosphonateOsteoporosisStrong evidence

Bisphosphonates

A medicine class that includes alendronate, risedronate, ibandronate, and zoledronic acid. These drugs slow bone breakdown and reduce fracture risk in appropriate patients.

View evidence note

Open mechanism, evidence, safety, and connected condition

What it is

Bisphosphonates bind to bone and reduce osteoclast-driven resorption. Oral and intravenous options differ in dosing, absorption, fracture evidence, kidney restrictions, and convenience.

Evidence snapshot

Bisphosphonates are established first-line options for many people at elevated fracture risk. The best drug, route, treatment duration, and possible pause depend on fracture history, bone density, age, and ongoing risk.

Safety focus

Oral products require exact administration to reduce esophageal injury. Kidney function, low calcium, dental plans, and rare osteonecrosis of the jaw or atypical femur fracture risk need review; new thigh or groin pain deserves prompt assessment.

Connected condition

Osteoporosis overview →

Evidence rating reviewed July 2026. Source: NIAMS osteoporosis diagnosis and treatment guide.

Move

Lifestyle · Exercise and fall preventionOsteoporosisStrong evidence

Bone-safe exercise and fall prevention

A tailored combination of resistance, weight-bearing, posture, and balance training plus practical steps to reduce falls and fractures.

View evidence note

Open mechanism, evidence, safety, and connected condition

What it is

Programs build muscle, coordination, balance, and safe movement while addressing vision, footwear, home hazards, medicines, and other fall risks. A physical therapist can adapt movement after fractures or for very high risk.

Evidence snapshot

Exercise and fall prevention are core components of osteoporosis care. They improve function and reduce fall risk, complementing rather than replacing fracture-prevention medicine when medication is indicated.

Safety focus

High-impact loading, forceful spinal flexion, rapid twisting, or poorly controlled lifting may be unsafe with vertebral osteoporosis. New severe back, hip, or groin pain should be assessed before continuing.

Connected condition

Osteoporosis overview →

Evidence rating reviewed July 2026. Sources: NIAMS exercise and bone health guide and NIAMS osteoporosis treatment guide.

SNRI

Prescription medication · SNRI4 prominent indications

Duloxetine

An SNRI that changes serotonin and norepinephrine signaling in mood, anxiety, and pain pathways. Dosing goals and outcome evidence differ by indication.

Painful diabetic peripheral neuropathyStrong evidence Reduces neuropathic pain symptoms without repairing the underlying nerve damage. View evidence note

What it is

Duloxetine increases serotonin and norepinephrine signaling in pathways involved in pain modulation. It may be especially useful when depression or anxiety coexists.

Evidence snapshot

Guidelines support SNRIs as an effective medication class for painful diabetic polyneuropathy. Benefit is symptom relief; underlying causes and foot-safety risks still need care.

Safety focus

Nausea, sleep change, dizziness, sweating, sexual effects, blood-pressure changes, low sodium, liver concerns, interactions, and withdrawal symptoms matter.

Connected condition

Peripheral neuropathy overview →

Evidence rating reviewed July 2026. Sources: AAN painful diabetic polyneuropathy guideline and FDA duloxetine prescribing information.

Major depressionStrong evidence Treats depressive symptoms as a second-generation antidepressant. View evidence note

What it is

Duloxetine is an SNRI antidepressant. Selection may be influenced by coexisting pain, prior response, blood pressure, liver health, interactions, and tolerability.

Evidence snapshot

Second-generation antidepressants are guideline-supported initial options for moderate-to-severe major depression. No single antidepressant is best for everyone.

Safety focus

Monitor for worsening depression or suicidal thinking, especially early in treatment. Screen for bipolar disorder and review serotonin syndrome, bleeding, liver, blood-pressure, and discontinuation risks.

Connected condition

Depression overview →

Evidence rating reviewed August 2026. Sources: ACP major depression guideline and FDA duloxetine prescribing information.

Generalized anxiety disorderStrong evidence Reduces persistent anxiety, with benefit usually building over several weeks. View evidence note

What it is

Duloxetine is one of several SSRI or SNRI options used for GAD. Choice depends on other symptoms, prior treatment, interactions, side effects, and patient preferences.

Evidence snapshot

SNRIs are established medication options for GAD and can be combined with psychotherapy. They are generally preferred over long-term benzodiazepine treatment.

Safety focus

Early nausea, sleep change, agitation, sweating, sexual effects, and blood-pressure change can occur. Mood monitoring and gradual prescriber-guided tapering are important.

Connected condition

Generalized anxiety disorder overview →

Evidence rating reviewed August 2026. Sources: NIMH generalized anxiety disorder guide and FDA duloxetine prescribing information.

Fibromyalgia and chronic musculoskeletal painStrong evidence Modifies central pain signaling to reduce pain and improve function for some people. View evidence note

What it is

Duloxetine is approved for fibromyalgia and chronic musculoskeletal pain, including chronic low-back pain and osteoarthritis-related pain in studied settings.

Evidence snapshot

Controlled trials support modest average pain improvement for these indications. Benefit varies, and medication is usually one part of a broader plan that includes activity, sleep, and functional goals.

Safety focus

The same antidepressant safety considerations apply. Liver disease, substantial alcohol use, uncontrolled narrow-angle glaucoma, blood-pressure changes, and interacting medicines require particular review.

Connected condition

Fibromyalgia →
Low-back pain →

Evidence rating reviewed August 2026. Source: FDA duloxetine prescribing information.

GBP

Prescription medication · Gabapentinoid3 prominent indications

Pregabalin

A gabapentinoid that reduces excitatory neurotransmitter release. Dose, treatment goals, and outcome evidence differ across neuropathic pain, fibromyalgia, and seizure therapy.

Neuropathic painStrong evidence Treats neuropathic pain associated with diabetic neuropathy, shingles, or spinal-cord injury. View evidence note

What it is

Pregabalin binds the alpha-2-delta subunit of voltage-gated calcium channels. Dose is adjusted for kidney function, and the medicine may affect sleep as well as pain.

Evidence snapshot

Gabapentinoids are an effective guideline-supported class for painful diabetic polyneuropathy, and pregabalin is also approved for postherpetic neuralgia and neuropathic pain after spinal-cord injury.

Safety focus

Dizziness, sleepiness, blurred vision, swelling, weight gain, falls, misuse, and respiratory depression risk with opioids or other sedatives require attention. Do not stop abruptly.

Connected condition

Peripheral neuropathy overview →

Evidence rating reviewed July 2026. Sources: AAN painful diabetic polyneuropathy guideline and FDA pregabalin review.

FibromyalgiaStrong evidence Reduces centralized pain and may improve sleep for some people. View evidence note

What it is

Pregabalin changes excitatory signaling involved in central pain amplification. It is one option within a broader plan that typically includes activity, sleep, pacing, and functional goals.

Evidence snapshot

Controlled trials support pregabalin for fibromyalgia, with modest average improvements and meaningful benefit for a subset of patients. Response should be reassessed rather than assumed.

Safety focus

Sleepiness, dizziness, swelling, weight gain, blurred vision, falls, and additive sedation can limit treatment. Kidney function guides dosing.

Connected condition

Fibromyalgia overview →

Evidence rating reviewed August 2026. Source: FDA pregabalin review.

Focal-onset seizures (adjunctive therapy)Strong evidence Adds to other antiseizure treatment to reduce focal-onset seizure frequency. View evidence note

What it is

Pregabalin is used as add-on rather than stand-alone therapy for focal-onset seizures. Neurology follow-up guides dose, response assessment, and changes to the overall regimen.

Evidence snapshot

Clinical trials and FDA review support pregabalin as adjunctive therapy for focal-onset seizures. The evidence rating is specific to add-on treatment, not every seizure type.

Safety focus

Do not stop abruptly because sudden withdrawal can increase seizure risk. Sedation, dizziness, swelling, respiratory depressant combinations, and kidney function require review.

Connected condition

This indication does not yet have a dedicated condition overview in the library.

Evidence rating reviewed August 2026. Source: FDA pregabalin review.

GF

Lifestyle · Medical nutrition therapyCeliac diseaseStrong evidence

Strict gluten-free diet for celiac disease

Lifelong avoidance of wheat, barley, rye, and clinically meaningful gluten cross-contact after the diagnosis has been properly established.

View evidence note

Open mechanism, evidence, safety, and connected condition

What it is

The diet removes the immune trigger while retaining naturally gluten-free grains and a nutritionally complete eating pattern. Label reading, food preparation, restaurants, medications, supplements, and shared kitchens may require practical planning.

Evidence snapshot

A strict gluten-free diet is the treatment for celiac disease. Most people experience symptom improvement and intestinal healing, though healing time and the relationship between symptoms and exposure vary.

Safety focus

Do not start before diagnostic testing without clinical advice. Poorly planned restriction can reduce fiber, iron, B vitamins, and food variety; persistent symptoms require investigation rather than progressively broader elimination.

Connected condition

Celiac disease overview →

Evidence rating reviewed July 2026. Sources: NIDDK celiac disease treatment guide and AGA diagnosis and monitoring guidance.

RDN

Nutrition care · MonitoringCeliac diseaseStrong evidence

Celiac dietitian and deficiency care

Specialist nutrition guidance plus evaluation and correction of documented deficiencies, hidden exposure, and complications during follow-up.

View evidence note

Open mechanism, evidence, safety, and connected condition

What it is

A celiac-experienced dietitian reviews labels, cross-contact, meal balance, access, and symptoms. Clinical follow-up may assess blood counts, iron, folate, B12, vitamin D, calcium, bone health, antibody trends, and other needs.

Evidence snapshot

Authoritative guidance recommends dietitian education and individualized correction of deficiencies as part of treatment. Follow-up helps distinguish ongoing gluten exposure from lactose intolerance, IBS, microscopic colitis, or rare refractory disease.

Safety focus

High-dose supplements can cause toxicity or interactions and should target documented need. Persistent weight loss, anemia, diarrhea, or pain deserves medical reassessment rather than self-directed dietary restriction.

Connected condition

Celiac disease overview →

Evidence rating reviewed July 2026. Source: NIDDK celiac disease treatment and follow-up guide.

PAP

Breathing device · Positive airway pressureObstructive sleep apneaStrong evidence

CPAP and positive airway pressure therapy

A bedside device that delivers pressurized air through a mask to prevent the upper airway from collapsing during sleep.

View evidence note

Open mechanism, evidence, safety, and connected condition

What it is

Continuous, auto-adjusting, or bilevel positive airway pressure may be prescribed based on the sleep study and clinical context. Mask style, fit, humidification, pressure comfort, leak, and coaching strongly affect consistent use.

Evidence snapshot

PAP is a highly effective treatment for controlling obstructive breathing events. It can improve snoring, sleep quality, and daytime sleepiness; benefits depend on using it whenever sleeping.

Safety focus

Nasal dryness, congestion, skin irritation, air leak, and aerophagia are often manageable with equipment adjustment. Persistent severe bloating, pressure intolerance, or worsening symptoms needs review rather than abandonment without an alternative plan.

Connected condition

Obstructive sleep apnea overview →

Evidence rating reviewed July 2026. Sources: NHLBI CPAP guide and NHLBI sleep apnea treatment guide.

OA

Oral appliance · Dental sleep medicineObstructive sleep apneaStrong evidence

Custom oral appliance therapy for OSA

A custom, adjustable mouthpiece that advances the lower jaw to help keep the airway open during sleep.

View evidence note

Open mechanism, evidence, safety, and connected condition

What it is

A qualified dentist fits and titrates a mandibular advancement device after a sleep clinician prescribes it. Follow-up sleep testing verifies whether it adequately controls breathing events.

Evidence snapshot

Guidelines support custom titratable appliances for adults with OSA who prefer an alternative to CPAP or cannot tolerate it. CPAP generally reduces breathing events more completely, while an appliance may be easier for some people to use consistently.

Safety focus

Jaw discomfort, tooth movement, bite change, dry mouth, or excess saliva can occur. Dental health and jaw-joint status need assessment, with ongoing dental monitoring and sleep-clinician follow-up.

Connected condition

Obstructive sleep apnea overview →

Evidence rating reviewed July 2026. Sources: AASM/AADSM oral-appliance guideline summary and NHLBI treatment guide.

ARNI

Prescription medication · ARNIHeart failure with reduced ejection fractionStrong evidence

Angiotensin receptor–neprilysin inhibitor therapy

Sacubitril/valsartan combines angiotensin-receptor blockade with neprilysin inhibition to improve cardiovascular signaling in eligible people with HFrEF.

View evidence note

Open mechanism, evidence, safety, and connected condition

What it is

The valsartan component blocks angiotensin II effects, while sacubitril increases beneficial natriuretic-peptide activity. It is one of four foundational medication classes for HFrEF and replaces—not combines with—an ACE inhibitor.

Evidence snapshot

The AHA/ACC/HFSA guideline recommends ARNI as first-line renin-angiotensin system inhibition for symptomatic HFrEF when feasible, reducing cardiovascular death and heart-failure hospitalization.

Safety focus

Low blood pressure, kidney-function change, high potassium, and rare angioedema require monitoring. It must not overlap with an ACE inhibitor; a washout interval is required. Pregnancy is contraindicated.

Connected condition

Heart failure overview →

Evidence rating reviewed July 2026. Sources: 2022 AHA/ACC/HFSA guideline key perspectives and AHA heart-failure medication guide.

MRA

Prescription medication · MRA3 prominent indications

Mineralocorticoid receptor antagonists

Spironolactone and eplerenone block aldosterone signaling. The goal, dose, monitoring, and strength of evidence differ across heart failure and forms of hypertension.

Heart failure with reduced ejection fractionStrong evidence Reduces hospitalization and mortality in eligible people with symptomatic HFrEF. View evidence note

What it is

MRAs limit sodium retention, potassium loss, fibrosis, and harmful aldosterone effects. They are foundational HFrEF therapy even without obvious fluid overload.

Evidence snapshot

Guidelines strongly recommend an MRA for eligible symptomatic HFrEF patients with adequate kidney function and potassium control as part of multidrug guideline-directed therapy.

Safety focus

High potassium and worsening kidney function can be serious, so baseline and follow-up laboratory monitoring are essential. Interacting medicines and potassium supplements require review.

Connected condition

Heart failure overview →

Evidence rating reviewed July 2026. Sources: 2022 AHA/ACC/HFSA guideline key perspectives and AHA heart-failure medication guide.

Resistant hypertensionStrong evidence Adds aldosterone blockade when blood pressure remains high on an optimized multidrug regimen. View evidence note

What it is

Spironolactone or eplerenone may be added after confirming true resistant hypertension, addressing adherence and measurement, and optimizing the usual three-drug regimen.

Evidence snapshot

AHA guidance places an MRA among the preferred additions for resistant hypertension. The rating does not apply to routine first-line treatment of uncomplicated high blood pressure.

Safety focus

Kidney function and potassium determine eligibility and monitoring. Spironolactone can cause breast tenderness, enlargement, menstrual changes, or sexual effects.

Connected condition

High blood pressure overview →

Evidence rating reviewed August 2026. Source: AHA resistant hypertension management commentary.

Primary aldosteronismModerate evidence Provides aldosterone-specific medical therapy for bilateral disease or when surgery is not chosen. View evidence note

What it is

MRAs directly block the excess aldosterone driving sodium retention, hypertension, and sometimes low potassium. Spironolactone is generally preferred for cost and availability; eplerenone may reduce hormone-related effects.

Evidence snapshot

The Endocrine Society suggests MRA therapy for bilateral primary aldosteronism and for people with lateralizing disease who do not pursue surgery. The recommendation is clinically important but based on lower-certainty comparative evidence.

Safety focus

Potassium, kidney function, blood pressure, and renin response guide titration. Advanced kidney impairment, high potassium, pregnancy, and interacting medicines can make treatment unsafe.

Connected condition

This indication does not yet have a dedicated condition overview in the library.

Evidence rating reviewed August 2026. Source: 2025 Endocrine Society primary aldosteronism guideline.

ARB

Prescription medication · ARB3 prominent indications

Angiotensin receptor blockers

Medicines such as losartan, valsartan, and candesartan block angiotensin II. Their goal and evidence differ across blood pressure, kidney disease, and heart failure.

High blood pressureStrong evidenceRelaxes blood vessels and reduces sodium-retaining signals.View evidence note

What it is

ARBs are established first-line blood-pressure medicines, often selected when an ACE inhibitor causes cough.

Evidence snapshot

Current hypertension guidance includes ARBs among the principal first-line classes for appropriate adults.

Safety focus

Blood pressure, kidney function, and potassium require monitoring. Pregnancy is contraindicated; combining an ARB with an ACE inhibitor is generally avoided.

Connected condition

High blood pressure overview →

Evidence rating reviewed August 2026. Source: 2025 AHA/ACC blood pressure guideline summary.

Chronic kidney disease with albuminuriaStrong evidenceReduces albuminuria and slows progression in recommended CKD groups.View evidence note

What it is

An ARB may substitute for an ACE inhibitor when renin–angiotensin system blockade is indicated, especially with albumin in the urine.

Evidence snapshot

KDIGO recommends an ACE inhibitor or ARB for several CKD groups with moderately or severely increased albuminuria.

Safety focus

Creatinine and potassium are checked after starting or changing dose. Dehydration, interacting medicines, or renal-artery disease can increase risk.

Connected condition

Chronic kidney disease overview →

Evidence rating reviewed August 2026. Source: KDIGO 2024 CKD guideline.

Heart failure with reduced ejection fractionStrong evidenceProvides renin–angiotensin blockade when ARNI or ACE inhibitor therapy is not feasible.View evidence note

What it is

Selected ARBs reduce harmful vascular and remodeling signals in HFrEF, usually as an alternative rather than an addition to ARNI or ACE inhibitor therapy.

Evidence snapshot

Heart-failure guidelines support an ARB when ARNI therapy is not feasible and an ACE inhibitor is not tolerated.

Safety focus

Low blood pressure, kidney-function change, and high potassium require monitoring. Treatment selection depends on the full heart-failure regimen.

Connected condition

Heart failure overview →

Evidence rating reviewed August 2026. Source: American Heart Association heart-failure medication guide.

TZD

Prescription medication · DiureticHigh blood pressureStrong evidence

Thiazide and thiazide-like diuretics

Medicines such as chlorthalidone, hydrochlorothiazide, and indapamide help the kidneys excrete sodium and lower blood pressure.

View evidence note

Open mechanism, evidence, safety, and connected condition

What it is

A long-established first-line medicine class used alone or with complementary blood-pressure drugs.

Evidence snapshot

Guidelines support thiazide-type medicines for blood-pressure lowering and prevention of cardiovascular events.

Safety focus

Sodium, potassium, kidney function, uric acid, glucose, dizziness, and dehydration may need monitoring.

Connected condition

High blood pressure overview →

Evidence rating reviewed August 2026. Source: 2025 AHA/ACC blood pressure guideline summary.

CCB

Prescription medication · CCB2 prominent indications

Calcium-channel blockers

This broad class includes blood-vessel–selective medicines such as amlodipine and heart-rate–slowing medicines such as diltiazem and verapamil.

High blood pressureStrong evidenceDihydropyridine CCBs relax arterial smooth muscle.View evidence note

What it is

Amlodipine and related medicines primarily widen arteries and are common first-line choices.

Evidence snapshot

Current guidance includes long-acting dihydropyridine CCBs among first-line blood-pressure medicines.

Safety focus

Ankle swelling, flushing, headache, dizziness, and gum enlargement can occur. Some agents interact with grapefruit or other medicines.

Connected condition

High blood pressure overview →

Evidence rating reviewed August 2026. Source: 2025 AHA/ACC blood pressure guideline summary.

Atrial fibrillation rate controlStrong evidenceDiltiazem or verapamil slows conduction through the AV node.View evidence note

What it is

Non-dihydropyridine CCBs can slow ventricular rate in AF; amlodipine does not provide this effect.

Evidence snapshot

AF guidelines support diltiazem or verapamil for rate control in appropriate patients.

Safety focus

These medicines can cause slow heart rate or low blood pressure and are generally avoided in HFrEF because they may weaken contraction.

Connected condition

Atrial fibrillation overview →

Evidence rating reviewed August 2026. Source: ACC summary of 2024 ESC atrial-fibrillation guidance.

GLP

Prescription medication · Incretin therapy2 prominent indications

GLP-1–based therapy

GLP-1 receptor agonists and dual GIP/GLP-1 medicines affect glucose, appetite, and gastric emptying. Products and doses are indication specific.

Type 2 diabetesStrong evidenceLowers glucose, often supports weight loss, and offers cardiovascular benefit with selected agents.View evidence note

What it is

Selection depends on glucose goals, cardiovascular and kidney disease, weight goals, access, and tolerance.

Evidence snapshot

ADA standards support GLP-1–based therapy as a major individualized diabetes option.

Safety focus

Gastrointestinal effects, gallbladder disease, pancreatitis concerns, dehydration, pregnancy, retinopathy context, and labeled thyroid-tumor warnings require review.

Connected condition

Type 2 diabetes overview →

Evidence rating reviewed August 2026. Source: ADA 2026 Standards of Care.

Long-term obesity treatmentStrong evidenceReduces appetite and produces substantial average weight loss with obesity-labeled products and doses.View evidence note

What it is

Obesity-labeled semaglutide, liraglutide, and dual GIP/GLP-1 tirzepatide are used with supportive lifestyle care. Diabetes and obesity formulations are not automatically interchangeable.

Evidence snapshot

Large randomized trials show clinically meaningful weight loss and improvement in several weight-related complications; continued treatment is usually needed to maintain benefit.

Safety focus

Product-specific contraindications, lean-mass preservation, nutrition, gallbladder disease, gastrointestinal effects, pregnancy, and access require review. Avoid compounded or counterfeit products of uncertain quality.

Connected condition

Obesity overview →

Evidence rating reviewed August 2026. Sources: ADA 2026 Standards of Care and AGA obesity pharmacotherapy guideline.

IN

Prescription medication · InsulinType 2 diabetesStrong evidence

Insulin therapy for type 2 diabetes

Injected or pump-delivered insulin replaces or supplements the body's insulin when other approaches are insufficient or rapid control is needed.

View evidence note

Open mechanism, evidence, safety, and connected condition

What it is

Plans may begin with long-acting basal insulin and become more intensive when needed. Education, glucose monitoring, and dose-adjustment support are essential.

Evidence snapshot

Insulin reliably lowers glucose and is essential for severe hyperglycemia, catabolic symptoms, acute illness, or when individualized goals are not met otherwise.

Safety focus

Low blood sugar is the main acute risk; weight gain and injection-site issues can occur. Doses must be individualized around meals, activity, kidney function, and other medicines.

Connected condition

Type 2 diabetes overview →

Evidence rating reviewed August 2026. Source: ADA 2026 Standards of Care.

EZ

Prescription medication · Cholesterol absorption inhibitorHyperlipidemiaStrong evidence

Ezetimibe

A nonstatin medicine that reduces intestinal cholesterol absorption and lowers LDL cholesterol, commonly added when statin therapy alone is insufficient.

View evidence note

Open mechanism, evidence, safety, and connected condition

What it is

Ezetimibe is an oral once-daily option used with a statin or, in selected cases, when statins are not tolerated.

Evidence snapshot

Guidelines support ezetimibe as a principal nonstatin addition when further LDL lowering is needed; outcome benefit is strongest in higher-risk patients receiving statin therapy.

Safety focus

It is usually well tolerated. Liver tests, muscle symptoms, and interactions may matter, especially when combined with a statin.

Connected condition

Hyperlipidemia overview →

Evidence rating reviewed August 2026. Source: 2026 ACC/AHA cholesterol guideline announcement.

nsMRA

Prescription medication · Nonsteroidal MRACKD with type 2 diabetesStrong evidence

Finerenone

A nonsteroidal mineralocorticoid receptor antagonist used to reduce kidney and cardiovascular risk in eligible adults with CKD and type 2 diabetes.

View evidence note

Open mechanism, evidence, safety, and connected condition

What it is

Finerenone blocks mineralocorticoid-receptor signaling implicated in inflammation and fibrosis. It is not interchangeable with spironolactone for every use.

Evidence snapshot

Trials and KDIGO guidance support finerenone for eligible people with type 2 diabetes, CKD, and persistent albuminuria despite standard renin–angiotensin system therapy.

Safety focus

Potassium and kidney function determine eligibility, dose, and follow-up. High potassium and strong CYP3A4 interactions can make treatment unsafe.

Connected condition

Chronic kidney disease →
Type 2 diabetes →

Evidence rating reviewed August 2026. Source: KDIGO 2024 CKD guideline.

H1

OTC medication · AntihistamineSeasonal allergiesStrong evidence

Second-generation oral antihistamines

Cetirizine, loratadine, fexofenadine, and related medicines reduce sneezing, itching, and runny nose with less sedation than older antihistamines.

View evidence note

Open mechanism, evidence, safety, and connected condition

What it is

These medicines block peripheral H1 histamine receptors and work best for histamine-driven nasal and eye symptoms.

Evidence snapshot

Allergy guidance supports newer oral antihistamines for seasonal allergic rhinitis, particularly sneezing and itching; they are usually less effective for congestion than a nasal steroid.

Safety focus

Drowsiness can still occur, especially with cetirizine. Kidney function, pregnancy, alcohol, driving, and other sedating medicines may affect selection.

Connected condition

Seasonal allergies overview →

Evidence rating reviewed August 2026. Source: AAAAI hay fever and rhinitis guide.

NS

OTC or prescription nasal medicineSeasonal allergiesStrong evidence

Intranasal corticosteroids

Anti-inflammatory nasal sprays such as fluticasone, budesonide, and triamcinolone treat congestion, sneezing, itching, and runny nose.

View evidence note

Open mechanism, evidence, safety, and connected condition

What it is

Correct daily technique directs medicine into the nasal passages while minimizing throat exposure; full benefit may take several days.

Evidence snapshot

Practice parameters prefer intranasal corticosteroid monotherapy for persistent moderate-to-severe allergic rhinitis because it treats the broadest range of nasal symptoms.

Safety focus

Dryness, irritation, and nosebleeds are most common. Aim away from the nasal septum; persistent bleeding, eye disease, or use in children warrants guidance.

Connected condition

Seasonal allergies overview →

Evidence rating reviewed August 2026. Source: Rhinitis 2020 practice parameter.

AIT

Specialist treatment · ImmunotherapySeasonal allergiesStrong evidence

Allergen immunotherapy

Allergy shots or selected under-the-tongue tablets gradually expose the immune system to a confirmed trigger to reduce future allergic symptoms.

View evidence note

Open mechanism, evidence, safety, and connected condition

What it is

An allergist matches treatment to clinically relevant testing. It requires a build-up and maintenance course rather than immediate symptom relief.

Evidence snapshot

Immunotherapy can reduce symptoms and medication use and may provide lasting benefit after a completed course in appropriately selected people.

Safety focus

Local reactions are common and systemic allergic reactions can occur. Injections require observation; uncontrolled asthma raises risk and must be addressed.

Connected condition

Seasonal allergies overview →

Evidence rating reviewed August 2026. Source: AAAAI immunotherapy guide.

AIR

Prescription inhaler · ICS/formoterolAsthmaStrong evidence

ICS–formoterol anti-inflammatory reliever

A combination inhaler that delivers an inhaled corticosteroid with rapid-onset formoterol whenever relief is needed; some plans also use it for maintenance.

View evidence note

Open mechanism, evidence, safety, and connected condition

What it is

Known as AIR when used for relief and MART when used for both maintenance and relief. The exact inhaler, dose, and regulatory availability matter.

Evidence snapshot

GINA prefers ICS-containing reliever strategies because they reduce severe exacerbations compared with short-acting bronchodilator-only treatment.

Safety focus

Technique, adherence, mouth rinsing, maximum daily use, and an action plan are important. Rapidly worsening symptoms or poor response require urgent care.

Connected condition

Asthma overview →

Evidence rating reviewed August 2026. Source: GINA 2026 asthma strategy.

3×

Prescription inhaler · ICS/LABA/LAMACOPDStrong evidence

Triple inhaler therapy for COPD

An inhaled corticosteroid plus two long-acting bronchodilators for selected people with continued exacerbations despite optimized bronchodilator treatment.

View evidence note

Open mechanism, evidence, safety, and connected condition

What it is

Triple therapy combines ICS, LABA, and LAMA in one or more inhalers. Blood eosinophils and exacerbation history help estimate likely ICS benefit.

Evidence snapshot

For selected patients with recurrent COPD exacerbations, triple therapy reduces exacerbations more than dual bronchodilation; it is not routine for everyone with COPD.

Safety focus

ICS can increase pneumonia risk in some people. Technique, oral thrush prevention, anticholinergic effects, heart rhythm, and device usability need review.

Connected condition

COPD overview →

Evidence rating reviewed August 2026. Source: GOLD 2026 COPD report.

Q

Behavioral treatment · CounselingTobacco dependence and COPDStrong evidence

Behavioral counseling and quitline support

Individual, group, telephone, text, or web-based support builds a quit plan, coping skills, medication use, and recovery after slips.

View evidence note

Open mechanism, evidence, safety, and connected condition

What it is

Support ranges from brief clinician advice to intensive counseling and free quitlines. It identifies triggers, plans for withdrawal, and treats a slip as information rather than failure.

Evidence snapshot

Counseling improves quit success, with greater benefit from more contact. Combining counseling with medication can more than double the chance of quitting.

Safety focus

Pregnancy, severe mental-health symptoms, other substance use, and major stressors may require tailored support. New depression or self-harm thoughts need prompt care.

Connected condition

Tobacco dependence →
COPD →

Evidence rating reviewed August 2026. Source: CDC clinical tobacco-dependence guidance.

BIO

Specialist medication · Biologic2 prominent indications

Targeted biologic therapy

Injected medicines that block specific immune pathways. The eligible phenotype, exact drug, outcomes, and evidence differ by disease.

Severe asthmaStrong evidenceTargets IgE, eosinophils, or type-2 inflammatory pathways in eligible phenotypes.View evidence note

What it is

Biologic selection follows confirmation of severe asthma, optimized inhaled treatment, adherence and technique review, and phenotype testing.

Evidence snapshot

In eligible severe asthma populations, targeted biologics reduce exacerbations and oral-steroid exposure and may improve control.

Safety focus

Injection reactions and rare serious allergy can occur. Eligibility, monitoring, vaccines, parasitic infection risk, and step-down decisions require specialist care.

Connected condition

Asthma overview →

Evidence rating reviewed August 2026. Source: GINA 2026 asthma strategy.

Moderate-to-severe atopic dermatitisStrong evidenceTargets immune signaling when optimized topical therapy is insufficient.View evidence note

What it is

Agents such as dupilumab and tralokinumab target type-2 inflammatory pathways; age approvals and dosing differ.

Evidence snapshot

AAD guidelines strongly recommend several biologics for adults with moderate-to-severe atopic dermatitis needing systemic therapy.

Safety focus

Eye inflammation, injection reactions, infection context, vaccines, pregnancy, cost, and access require individualized review.

Connected condition

Atopic dermatitis overview →

Evidence rating reviewed August 2026. Source: AAD atopic dermatitis guideline.

MB

Skin care · Moisturizer and bathingAtopic dermatitisStrong evidence

Moisturizer and skin-barrier care

Regular fragrance-free moisturizer, gentle bathing, and trigger reduction form the daily foundation of eczema care.

View evidence note

Open mechanism, evidence, safety, and connected condition

What it is

Thick creams or ointments are applied generously, especially soon after lukewarm bathing, alongside gentle fragrance-free cleansers when needed.

Evidence snapshot

Moisturizers reduce dryness, support the skin barrier, and can reduce flare frequency and the amount of anti-inflammatory medicine needed.

Safety focus

Fragrance and botanical ingredients can irritate or sensitize. Weeping, crusting, rapidly spreading redness, pain, fever, or eye involvement needs medical review.

Connected condition

Atopic dermatitis overview →

Evidence rating reviewed August 2026. Source: AAD atopic dermatitis guideline.

TS

Prescription topical medicationAtopic dermatitisStrong evidence

Steroid-sparing topical medicines

Topical calcineurin inhibitors, crisaborole, and topical ruxolitinib reduce inflammation without the same skin-thinning risk as corticosteroids.

View evidence note

Open mechanism, evidence, safety, and connected condition

What it is

These nonsteroid options are useful for sensitive areas, maintenance, or when corticosteroid exposure should be limited. Age and body-area approvals differ.

Evidence snapshot

AAD topical-therapy guidelines strongly recommend topical calcineurin inhibitors and other approved nonsteroid anti-inflammatory medicines for appropriate patients.

Safety focus

Burning or stinging can occur. Product-specific boxed warnings, infection, sun exposure, pregnancy, treatment area, and duration need review.

Connected condition

Atopic dermatitis overview →

Evidence rating reviewed August 2026. Source: AAD topical atopic dermatitis guideline summary.

CGRP

Prescription medication · CGRP-targeting2 prominent uses

CGRP-targeting migraine therapies

Small-molecule gepants and monoclonal antibodies target calcitonin gene-related peptide signaling for acute or preventive migraine treatment.

Acute migraine treatmentStrong evidenceSelected gepants treat an attack without constricting blood vessels.View evidence note

What it is

Ubrogepant, rimegepant, and zavegepant are used early in an attack and can be options when triptans are ineffective, poorly tolerated, or unsuitable.

Evidence snapshot

Randomized trials support pain freedom and relief of the most bothersome symptom at two hours for approved gepants.

Safety focus

Drug interactions, liver or kidney impairment, pregnancy, nausea, and frequency of use require review. Sudden new or atypical severe headache needs urgent assessment.

Connected condition

Migraine overview →

Evidence rating reviewed August 2026. Source: American Headache Society treatment guidance.

Migraine preventionStrong evidenceRegular dosing reduces monthly migraine burden.View evidence note

What it is

Preventive options include oral gepants and injectable CGRP or CGRP-receptor antibodies, with different schedules and administration routes.

Evidence snapshot

The American Headache Society considers CGRP-targeting therapies a first-line preventive option without requiring failure of older classes first.

Safety focus

Constipation, injection reactions, blood-pressure concerns with some products, interactions, pregnancy, and access matter. Response should be reassessed over time.

Connected condition

Migraine overview →

Evidence rating reviewed August 2026. Source: American Headache Society position statement.

H2

OTC or prescription medication · H2 blockerGERDModerate evidence

H2 receptor blockers

Medicines such as famotidine reduce stomach-acid production and can help intermittent or nighttime reflux symptoms.

View evidence note

Open mechanism, evidence, safety, and connected condition

What it is

H2 blockers work faster but suppress acid less strongly than proton pump inhibitors. Tolerance can reduce effect with continuous use.

Evidence snapshot

Guidance supports H2 blockers for mild or intermittent reflux and as a step-down option; PPIs are more effective for healing erosive esophagitis.

Safety focus

Kidney impairment may require dose adjustment. Persistent symptoms, trouble swallowing, bleeding, weight loss, anemia, or chest pain require evaluation.

Connected condition

GERD overview →

Evidence rating reviewed August 2026. Source: American Gastroenterological Association GERD guidance.

DORA

Prescription medication · Orexin antagonistChronic insomniaModerate evidence

Dual orexin receptor antagonists

Daridorexant, lemborexant, and suvorexant reduce wake-promoting orexin signaling to help with sleep onset, sleep maintenance, or both.

View evidence note

Open mechanism, evidence, safety, and connected condition

What it is

A newer hypnotic class considered after assessment of causes and usually alongside or after CBT-I, depending on severity, access, and preference.

Evidence snapshot

Controlled trials show modest improvements in sleep measures. Medication can be appropriate when CBT-I is unavailable, insufficient, or used in combination.

Safety focus

Next-day impairment, falls, unusual sleep behaviors, sleep paralysis, interactions, alcohol, pregnancy, and narcolepsy require attention. Use only when a full night's sleep is possible.

Connected condition

Chronic insomnia overview →

Evidence rating reviewed August 2026. Sources: AASM insomnia pharmacology guideline and current FDA prescribing information.

PT

Lifestyle · Exercise and rehabilitationOsteoarthritisStrong evidence

Exercise and physical therapy for osteoarthritis

Progressive strength, aerobic, mobility, and neuromuscular exercise improves pain and function; physical therapy helps tailor the plan.

View evidence note

Open mechanism, evidence, safety, and connected condition

What it is

A sustainable program matched to the affected joints, current capacity, goals, and barriers; aquatic exercise and assistive devices can expand access.

Evidence snapshot

Exercise is a core osteoarthritis treatment with consistent evidence for improving pain, physical function, and quality of life.

Safety focus

Some short-lived soreness is common, but marked swelling, instability, locking, injury, or rapidly worsening pain warrants assessment. Progress gradually.

Connected condition

Osteoarthritis overview →

Evidence rating reviewed August 2026. Source: NIAMS osteoarthritis treatment guide.

IBS

Prescription and OTC digestive medicines2 subtype-specific uses

IBS subtype-directed medicines

Medication choices differ substantially for constipation-predominant and diarrhea-predominant IBS, so benefits and safety are separated by subtype.

IBS with constipation (IBS-C)Strong evidenceSecretagogues and related medicines improve bowel movements and abdominal symptoms.View evidence note

What it is

Options include linaclotide, plecanatide, lubiprostone, and tenapanor after subtype confirmation and simpler measures.

Evidence snapshot

AGA guidance recommends or suggests several approved IBS-C medicines based on randomized trials, with varying certainty by agent.

Safety focus

Diarrhea, dehydration, pregnancy, bowel obstruction, age restrictions, cost, and product-specific contraindications require review.

Connected condition

IBS overview →

Evidence rating reviewed August 2026. Source: AGA IBS pharmacologic guidance.

IBS with diarrhea (IBS-D)Moderate evidenceSelected medicines target stool frequency, urgency, pain, or bloating.View evidence note

What it is

Options can include rifaximin, eluxadoline, alosetron for narrowly selected patients, and loperamide mainly for diarrhea control.

Evidence snapshot

AGA suggests several IBS-D medicines, but the strength and target outcomes vary; improving stool frequency alone does not guarantee global symptom relief.

Safety focus

Gallbladder status, pancreatitis risk, severe constipation, liver disease, pregnancy, infection, bleeding, weight loss, or nighttime symptoms change the approach.

Connected condition

IBS overview →

Evidence rating reviewed August 2026. Source: AGA IBS pharmacologic guidance.

AF

Specialist treatment · Rhythm control2 major strategies

Atrial fibrillation rhythm-control strategies

Antiarrhythmic medicines and catheter ablation aim to restore or maintain sinus rhythm; candidacy and risks differ substantially.

Antiarrhythmic medicinesStrong evidenceReduce recurrent AF and maintain sinus rhythm in selected patients.View evidence note

What it is

Drug selection depends on heart structure, coronary disease, kidney and liver function, QT interval, interactions, and whether supervised initiation is needed.

Evidence snapshot

Guidelines support rhythm-control medicine for suitable symptomatic patients and increasingly favor early rhythm control in selected people.

Safety focus

These medicines can cause new dangerous rhythms, organ toxicity, interactions, or slow heart rate. Anticoagulation decisions remain based on stroke risk, not apparent rhythm alone.

Connected condition

Atrial fibrillation overview →

Evidence rating reviewed August 2026. Source: 2023 ACC/AHA atrial-fibrillation guideline key perspectives.

Catheter ablationStrong evidenceElectrically isolates or modifies tissue that triggers or sustains AF.View evidence note

What it is

A heart-rhythm specialist threads catheters into the heart to deliver energy to targeted tissue. Repeat procedures may be needed.

Evidence snapshot

Ablation improves symptoms and reduces AF recurrence in selected patients and is first-line rhythm control for some symptomatic groups.

Safety focus

Bleeding, vascular injury, stroke, cardiac perforation, pulmonary-vein narrowing, rare esophageal injury, recurrence, and anesthesia risks require informed discussion.

Connected condition

Atrial fibrillation overview →

Evidence rating reviewed August 2026. Source: 2023 ACC/AHA atrial-fibrillation guideline key perspectives.

BONE

Prescription osteoporosis medication2 major strategies

Non-bisphosphonate osteoporosis medicines

Denosumab slows bone breakdown, while anabolic medicines build bone. They serve different risk groups and require planned sequencing.

DenosumabStrong evidenceBlocks RANK ligand to reduce bone resorption and fractures.View evidence note

What it is

A clinician-administered injection given on schedule for people at high fracture risk or when other options are unsuitable.

Evidence snapshot

Denosumab increases bone density and reduces vertebral, hip, and other fractures in appropriate osteoporosis populations.

Safety focus

Calcium and vitamin D status, kidney disease, dental health, infection, and rare jaw or atypical-femur complications matter. Stopping or delaying without follow-on therapy can cause rapid bone loss and vertebral fractures.

Connected condition

Osteoporosis overview →

Evidence rating reviewed August 2026. Source: NIAMS osteoporosis treatment guide.

Bone-building therapyStrong evidenceTeriparatide, abaloparatide, or romosozumab rapidly increases bone formation for very high fracture risk.View evidence note

What it is

Time-limited injectable treatment generally followed by an antiresorptive medicine to preserve gains.

Evidence snapshot

Anabolic therapy reduces fractures and is prioritized for very high-risk osteoporosis, such as recent or multiple vertebral fractures.

Safety focus

Product-specific limits include cardiovascular risk with romosozumab and contraindications related to skeletal malignancy or radiation for PTH analogs. Calcium abnormalities and treatment sequence require monitoring.

Connected condition

Osteoporosis overview →

Evidence rating reviewed August 2026. Source: NIAMS osteoporosis treatment guide.

TOP

Topical pain medication2 common options

Topical medicines for localized neuropathic pain

Capsaicin and lidocaine act locally and may reduce focal burning or shooting pain with less whole-body exposure than oral medicines.

CapsaicinModerate evidenceDesensitizes pain fibers through repeated low-dose use or a clinician-applied high-concentration patch.View evidence note

What it is

Available as lower-strength OTC products and a high-strength prescription patch for selected peripheral neuropathic pain.

Evidence snapshot

High-concentration capsaicin provides meaningful relief for some people with localized peripheral neuropathic pain; response varies.

Safety focus

Burning, redness, coughing from airborne residue, and accidental eye exposure can occur. Do not apply to broken skin; the high-dose patch requires trained application.

Connected condition

Peripheral neuropathy overview →

Evidence rating reviewed August 2026. Source: FDA-approved prescribing information and American Academy of Neurology painful diabetic neuropathy guidance.

Topical lidocaineLimited or mixed evidenceTemporarily reduces pain signaling in a small, superficial area.View evidence note

What it is

Patches, creams, and gels are sometimes used for focal neuropathic pain; prescription patch evidence is strongest for postherpetic neuralgia.

Evidence snapshot

Evidence outside postherpetic neuralgia is limited and inconsistent, though localized benefit and low systemic exposure can make a monitored trial reasonable.

Safety focus

Do not exceed product directions or combine multiple lidocaine products without guidance. Broken skin, heat, liver disease, and heart-rhythm medicines can increase toxicity risk.

Connected condition

Peripheral neuropathy overview →

Evidence rating reviewed August 2026. Sources: FDA-approved prescribing information and systematic evidence reviews.

OSA

Lifestyle and behavioral treatment2 targeted approaches

Weight and positional strategies for OSA

Weight management and side-sleeping target different contributors to airway collapse and work best for selected OSA patterns.

Weight management when relevantStrong evidenceReduces tissue-related airway narrowing and overall OSA severity.View evidence note

What it is

Nutrition, activity, behavioral treatment, anti-obesity medication, or bariatric surgery may be considered according to severity and eligibility.

Evidence snapshot

Meaningful weight loss often reduces apnea severity and cardiometabolic risk, though it may not eliminate OSA and PAP may still be needed.

Safety focus

Choose a sustainable, non-stigmatizing approach. Repeat sleep testing may be needed before changing PAP; medication and surgery have their own eligibility and risks.

Connected condition

Obstructive sleep apnea overview →

Evidence rating reviewed August 2026. Source: NHLBI sleep apnea treatment guide.

Positional therapyModerate evidenceDiscourages back-sleeping when breathing events are position dependent.View evidence note

What it is

Wearable trainers, specialized belts, or other methods help maintain side-sleeping after a sleep study confirms positional OSA.

Evidence snapshot

Positional therapy reduces events in positional OSA, but PAP generally controls breathing more completely and long-term adherence varies.

Safety focus

It should not replace effective PAP in severe or non-positional disease without clinician review. Shoulder, back, mobility, and pregnancy considerations may limit use.

Connected condition

Obstructive sleep apnea overview →

Evidence rating reviewed August 2026. Source: NHLBI sleep apnea treatment guide.

LOOP

Prescription medication · Loop diureticHeart failure congestionStrong evidence

Loop diuretics for heart-failure congestion

Furosemide, torsemide, and bumetanide remove excess sodium and fluid to improve swelling and breathlessness.

View evidence note

Open mechanism, evidence, safety, and connected condition

What it is

Loop diuretics are adjusted to congestion and kidney response. They relieve fluid symptoms but do not replace the foundational medicines that improve survival.

Evidence snapshot

Guidelines strongly recommend diuretics for heart-failure patients with fluid retention to relieve congestion, improve symptoms, and prevent worsening.

Safety focus

Daily weight plans, blood pressure, kidney function, sodium, potassium, magnesium, gout, dehydration, and hearing symptoms may need monitoring. Sudden worsening requires prompt care.

Connected condition

Heart failure overview →

Evidence rating reviewed August 2026. Source: American Heart Association heart-failure medication guide.

WM

Lifestyle · Multicomponent programObesityStrong evidence

Intensive behavioral weight management

Frequent, supportive coaching that combines individualized nutrition, activity, sleep, self-monitoring, problem-solving, and relapse planning without blame or extreme restriction.

View evidence note

Open mechanism, evidence, safety, and connected condition

What it is

A structured program focused on sustainable health and function. It can accompany medication or surgery and should account for culture, finances, disability, eating-disorder risk, and weight stigma.

Evidence snapshot

High-contact multicomponent programs produce clinically meaningful average weight loss and improve cardiometabolic risk, though response varies and ongoing support helps maintenance.

Safety focus

Very-low-calorie diets require medical supervision. Screen for disordered eating, medication-related weight gain, pregnancy, frailty, and conditions that alter nutrition or exercise safety.

Connected condition

Obesity overview →

Evidence rating reviewed August 2026. Source: NIDDK obesity treatment guide.

AOM

Prescription medication · Anti-obesity3 common options

Non-GLP-1 anti-obesity medicines

Long-term options with distinct mechanisms, expected weight effects, contraindications, and monitoring needs.

Phentermine/topiramate ERStrong evidenceReduces appetite through complementary stimulant and neurologic effects.View evidence note

What it is

An oral combination titrated gradually with response checkpoints.

Evidence snapshot

Trials support substantial average weight loss when combined with lifestyle care.

Safety focus

Pregnancy prevention is critical; heart rate, mood, cognition, glaucoma, kidney stones, and gradual discontinuation matter.

Connected condition

Obesity overview →

Evidence rating reviewed August 2026. Source: AGA obesity pharmacotherapy guideline.

Naltrexone/bupropion ERModerate evidenceTargets appetite and reward pathways.View evidence note

What it is

An oral combination titrated over several weeks.

Evidence snapshot

Trials show moderate average weight loss with lifestyle support.

Safety focus

Avoid with opioids, seizure disorders, uncontrolled hypertension, abrupt sedative withdrawal, pregnancy, or certain eating disorders; mood monitoring is important.

Connected condition

Obesity overview →

Evidence rating reviewed August 2026. Source: AGA obesity pharmacotherapy guideline.

OrlistatModerate evidenceReduces absorption of dietary fat.View evidence note

What it is

An oral lipase inhibitor available in prescription and lower-dose OTC forms.

Evidence snapshot

Weight loss is modest, and AGA suggests against routine use because benefits and burdens compare less favorably with other options.

Safety focus

Oily stool, urgency, fat-soluble vitamin deficiency, drug interactions, kidney stones, and rare liver injury require attention.

Connected condition

Obesity overview →

Evidence rating reviewed August 2026. Source: AGA obesity pharmacotherapy guideline.

MBS

Specialist procedure · Metabolic surgeryObesityStrong evidence

Metabolic and bariatric surgery

Sleeve gastrectomy, gastric bypass, and selected procedures alter stomach anatomy and metabolic signaling to produce large, durable health benefits.

View evidence note

Open mechanism, evidence, safety, and connected condition

What it is

Evaluation includes surgical risk, prior treatment, nutrition, mental health, eating patterns, reflux, medicines, fertility plans, and ability to complete lifelong follow-up.

Evidence snapshot

Surgery produces the greatest durable average weight loss and can improve diabetes, sleep apnea, cardiovascular risk, function, and survival in eligible groups.

Safety focus

Bleeding, leaks, clots, gallstones, reflux, ulcers, malnutrition, hypoglycemia, alcohol effects, pregnancy timing, and lifelong vitamin and laboratory monitoring require a specialized program.

Connected condition

Obesity overview →

Evidence rating reviewed August 2026. Source: ASMBS/IFSO surgery guidance.

DPP

Lifestyle · Yearlong coached programPrediabetesStrong evidence

Diabetes Prevention Program lifestyle intervention

A structured yearlong program using coaching, group support, nutrition change, physical activity, problem-solving, and modest weight loss when relevant.

View evidence note

Open mechanism, evidence, safety, and connected condition

What it is

CDC-recognized programs follow a quality-standardized curriculum in person or online with a trained lifestyle coach.

Evidence snapshot

The original DPP and real-world programs show substantial, durable reduction in progression to type 2 diabetes.

Safety focus

Activity and nutrition goals should be adapted for pregnancy, disability, frailty, eating disorders, glucose-lowering medicines, and cardiovascular symptoms.

Connected condition

Prediabetes overview →

Evidence rating reviewed August 2026. Source: CDC National DPP lifestyle change program.

APT

Medication · Antiplatelet2 prominent indications

Antiplatelet therapy

Aspirin and P2Y12 inhibitors such as clopidogrel reduce platelet-driven arterial clots. Agent and duration depend on the vascular event and bleeding risk.

Coronary artery diseaseStrong evidencePrevents heart attack and stent thrombosis in appropriate patients.View evidence note

What it is

Single or temporary dual antiplatelet therapy is selected around prior heart attack, stenting, bypass surgery, bleeding risk, and concurrent anticoagulation.

Evidence snapshot

Antiplatelets are foundational secondary prevention; dual therapy duration is individualized and is not automatically lifelong.

Safety focus

Bleeding, ulcers, allergy, interactions, surgery, and concurrent anticoagulants require review. Do not stop after a stent without the cardiology plan.

Connected condition

Coronary artery disease overview →

Evidence rating reviewed August 2026. Source: 2023 chronic coronary disease guideline.

Non-cardioembolic ischemic stroke or TIAStrong evidenceReduces recurrent arterial stroke when anticoagulation is not the indicated strategy.View evidence note

What it is

Single antiplatelet therapy is common long term; short dual therapy is reserved for defined early-arriving minor stroke or high-risk TIA groups.

Evidence snapshot

Cause-specific antithrombotic treatment reduces recurrence. Long-term dual therapy generally adds bleeding without benefit.

Safety focus

Brain bleeding must be excluded before acute treatment. Antiplatelet and anticoagulant combinations are rarely routine.

Connected condition

Stroke and TIA overview →

Evidence rating reviewed August 2026. Source: AHA/ASA secondary stroke-prevention guideline.

CR

Rehabilitation · Supervised programCoronary artery diseaseStrong evidence

Cardiac rehabilitation

A medically supervised program combining exercise, education, medication support, nutrition, risk-factor care, and psychosocial recovery after eligible cardiac events or procedures.

View evidence note

Open mechanism, evidence, safety, and connected condition

What it is

A phased outpatient program tailored to symptoms, fitness, heart function, procedures, work, and personal goals.

Evidence snapshot

Cardiac rehabilitation lowers morbidity and mortality and improves function and quality of life for eligible coronary-disease patients.

Safety focus

New or unstable symptoms require evaluation before exercise progression. Access barriers and referral gaps are common and worth addressing directly.

Connected condition

Coronary artery disease overview →

Evidence rating reviewed August 2026. Source: 2023 chronic coronary disease guideline.

REV

Specialist procedure · Revascularization2 major approaches

Coronary revascularization

PCI opens arteries with balloons and stents; CABG creates surgical bypasses. Anatomy, symptoms, urgency, diabetes, heart function, and preferences guide selection.

Percutaneous coronary interventionStrong evidenceOpens a narrowed artery with a catheter, usually placing a stent.View evidence note

What it is

PCI is urgent during many heart attacks and can relieve lifestyle-limiting angina despite medical therapy.

Evidence snapshot

PCI improves acute outcomes in indicated coronary syndromes and relieves symptoms in selected chronic disease.

Safety focus

Bleeding, kidney injury, artery damage, contrast allergy, restenosis, and strict antiplatelet adherence after stenting matter.

Connected condition

Coronary artery disease overview →

Evidence rating reviewed August 2026. Source: ACC coronary revascularization guideline hub.

Coronary artery bypass graftingStrong evidenceRoutes blood around blockages using surgical grafts.View evidence note

What it is

CABG is considered for left-main, complex multivessel, diabetic, or other anatomy where surgery offers better durability or survival.

Evidence snapshot

In defined anatomic and clinical groups, CABG improves survival and symptoms compared with medical therapy or PCI.

Safety focus

Stroke, bleeding, infection, kidney injury, arrhythmia, cognitive effects, recovery time, and graft durability require a heart-team discussion.

Connected condition

Coronary artery disease overview →

Evidence rating reviewed August 2026. Source: ACC coronary revascularization guideline hub.

NTG

Prescription medication · NitrateCoronary artery diseaseStrong evidence

Nitroglycerin and long-acting nitrates

Fast-acting nitroglycerin relieves angina episodes; longer-acting nitrates can reduce symptom frequency.

View evidence note

Open mechanism, evidence, safety, and connected condition

What it is

Nitrates widen veins and coronary arteries, reducing cardiac workload. Every patient needs a clear chest-pain emergency plan.

Evidence snapshot

Nitrates reliably relieve angina symptoms but have not shown the same long-term event prevention as statins or antiplatelets.

Safety focus

Never combine with PDE-5 erectile-dysfunction medicines or riociguat because life-threatening low blood pressure can occur. Headache and dizziness are common.

Connected condition

Coronary artery disease overview →

Evidence rating reviewed August 2026. Source: 2023 chronic coronary disease guideline.

911

Emergency treatment · Stroke center2 time-critical approaches

Acute ischemic stroke reperfusion

Clot-dissolving medicine and catheter thrombectomy restore brain blood flow in eligible patients. Treatment begins with emergency activation and imaging.

Intravenous thrombolysisStrong evidenceAlteplase or tenecteplase dissolves eligible clots in a limited time window.View evidence note

What it is

Emergency teams confirm timing, disability, brain imaging, blood pressure, bleeding risk, medicines, and exclusions before treatment.

Evidence snapshot

Rapid thrombolysis improves functional outcomes for eligible disabling ischemic stroke, with selected extended-window treatment using advanced imaging.

Safety focus

Brain or systemic bleeding is the central risk. Never self-treat possible stroke with aspirin before imaging.

Connected condition

Stroke and TIA overview →

Evidence rating reviewed August 2026. Source: 2026 AHA/ASA acute ischemic stroke guideline.

Endovascular thrombectomyStrong evidenceRemoves an accessible large-vessel clot with a catheter.View evidence note

What it is

A neurointerventional team reaches the blocked brain artery through a blood vessel and retrieves or aspirates the clot.

Evidence snapshot

Thrombectomy markedly improves outcomes for eligible large-vessel occlusion, including expanded selected late-window and larger-core groups.

Safety focus

Bleeding, vessel injury, contrast and anesthesia risks, and incomplete reperfusion can occur; transfer systems should avoid delay.

Connected condition

Stroke and TIA overview →

Evidence rating reviewed August 2026. Source: 2026 AHA/ASA acute ischemic stroke guideline.

SR

Rehabilitation · InterdisciplinaryStroke recoveryStrong evidence

Interdisciplinary stroke rehabilitation

Task-specific physical, occupational, speech-language, swallowing, cognitive, and psychological care beginning as soon as medically appropriate.

View evidence note

Open mechanism, evidence, safety, and connected condition

What it is

A coordinated program sets goals around mobility, communication, self-care, swallowing, cognition, mood, work, driving, and caregiver needs.

Evidence snapshot

Early organized rehabilitation improves independence and recovery; intensity and setting should match medical stability and tolerance.

Safety focus

Swallowing safety, falls, shoulder injury, blood pressure, fatigue, depression, seizures, and recurrent-stroke symptoms require active monitoring.

Connected condition

Stroke and TIA overview →

Evidence rating reviewed August 2026. Source: American Stroke Association rehabilitation guide.

AC

Prescription anticoagulation2 established strategies

Heparin-based and warfarin anticoagulation for VTE

Alternatives to DOACs for settings such as pregnancy, severe kidney disease, selected cancers, mechanical valves, or antiphospholipid syndrome.

Low-molecular-weight or unfractionated heparinStrong evidenceProvides rapid injectable anticoagulation.View evidence note

What it is

Enoxaparin and related LMWH products are common outpatient injections; IV unfractionated heparin is rapidly adjustable in hospital.

Evidence snapshot

Heparins are established initial VTE treatment and remain preferred in several pregnancy, renal, procedural, and cancer contexts.

Safety focus

Bleeding, kidney dosing, weight, platelet monitoring, heparin-induced thrombocytopenia, neuraxial procedures, and injection technique matter.

Connected condition

Venous thromboembolism overview →

Evidence rating reviewed August 2026. Source: ASH VTE guidance.

WarfarinStrong evidenceProvides oral vitamin-K antagonist treatment with INR-guided dosing.View evidence note

What it is

Warfarin starts slowly and usually overlaps with a faster anticoagulant during acute VTE. Dose is guided by INR.

Evidence snapshot

Warfarin effectively treats VTE and is preferred over DOACs for some antiphospholipid, valve, renal, or access situations.

Safety focus

Bleeding, pregnancy, food and drug interactions, illness, missed monitoring, and unstable INR require careful anticoagulation management.

Connected condition

Venous thromboembolism overview →

Evidence rating reviewed August 2026. Source: ASH anticoagulation management guide.

LBP

Non-drug treatment · Rehabilitation3 common approaches

Non-drug care for low-back pain

Active rehabilitation, behavioral skills, and selected hands-on or integrative treatments aim to restore function and reduce pain impact.

Exercise, education, and physical therapyStrong evidenceBuilds capacity, confidence, mobility, and self-management.View evidence note

What it is

Plans use tolerable activity, progressive strengthening and conditioning, pacing, and return to valued tasks rather than prolonged rest.

Evidence snapshot

Exercise and active rehabilitation improve chronic low-back-pain function and provide modest pain benefit.

Safety focus

New bowel or bladder loss, saddle numbness, progressive weakness, fever, or major trauma requires urgent evaluation before routine therapy.

Connected condition

Low-back pain overview →

Evidence rating reviewed August 2026. Source: VA/DoD low-back-pain guideline.

Cognitive behavioral therapy and mindfulnessModerate evidenceReduces fear, catastrophizing, distress, and pain interference.View evidence note

What it is

Skills-based care changes the response to pain while supporting pacing, sleep, activity, and functional goals.

Evidence snapshot

Psychological interventions produce modest improvements in chronic pain and function and work best as part of active care.

Safety focus

This does not imply pain is imaginary. Severe depression, trauma, substance use, or self-harm thoughts need appropriately specialized care.

Connected condition

Low-back pain overview →

Evidence rating reviewed August 2026. Source: VA/DoD low-back-pain guideline.

Acupuncture, spinal manipulation, or massageModerate evidenceMay provide short-term symptom and function benefit for selected people.View evidence note

What it is

These approaches vary by practitioner and technique and should support—not replace—active self-management.

Evidence snapshot

Average benefits are generally small to moderate and are not consistent for every person.

Safety focus

Use qualified practitioners; bleeding risk, osteoporosis, infection, neurologic deficits, fracture risk, and symptom worsening change suitability.

Connected condition

Low-back pain overview →

Evidence rating reviewed August 2026. Source: VA/DoD low-back-pain guideline.

NSAID

OTC or prescription medication · NSAID3 prominent indications

Oral NSAIDs

Ibuprofen, naproxen, celecoxib, and related medicines reduce prostaglandin-driven pain and inflammation. Benefit and risk differ by condition and duration.

Acute or chronic low-back painModerate evidenceProvides modest short-term pain relief.View evidence note

What it is

A short course may support activity when non-drug care alone is insufficient.

Evidence snapshot

NSAIDs provide small average pain benefit; functional recovery still relies on active care.

Safety focus

Ulcer, bleeding, kidney injury, blood pressure, heart disease, anticoagulants, pregnancy, and duplicate OTC products matter.

Connected condition

Low-back pain overview →

Evidence rating reviewed August 2026. Source: VA/DoD low-back-pain guideline.

Acute gout flareStrong evidenceRapidly suppresses joint inflammation when started early.View evidence note

What it is

A full anti-inflammatory regimen is selected around age, kidney and heart health, stomach risk, and other medicines.

Evidence snapshot

NSAIDs are one of three strongly recommended first-line flare treatments alongside colchicine and glucocorticoids.

Safety focus

Kidney disease, heart failure, anticoagulation, ulcers, and uncontrolled blood pressure often make another flare option safer.

Connected condition

Gout overview →

Evidence rating reviewed August 2026. Source: ACR gout guideline.

Osteoarthritis painStrong evidenceReduces pain when topical treatment is insufficient or impractical.View evidence note

What it is

Oral NSAIDs may be used intermittently or for limited periods alongside exercise and function-focused care.

Evidence snapshot

They improve osteoarthritis pain but do not reverse joint changes.

Safety focus

Use the lowest effective dose for the shortest needed time after reviewing gastrointestinal, kidney, heart, and bleeding risks.

Connected condition

Osteoarthritis overview →

Evidence rating reviewed August 2026. Source: NIAMS osteoarthritis treatment guide.

CIC

OTC and prescription digestive medicines3 treatment steps

Medicines for chronic constipation

Osmotic and stimulant laxatives are common early options; secretagogues or prucalopride are used when appropriate OTC therapy is insufficient.

Polyethylene glycolStrong evidenceDraws water into stool to improve frequency and consistency.View evidence note

What it is

PEG is a minimally absorbed osmotic powder mixed with liquid.

Evidence snapshot

AGA/ACG strongly recommends PEG for chronic idiopathic constipation.

Safety focus

Bloating, loose stool, dehydration, severe kidney or electrolyte disorders, obstruction symptoms, and pediatric use require context.

Connected condition

Chronic constipation overview →

Evidence rating reviewed August 2026. Source: AGA/ACG constipation guideline.

Stimulant laxativesStrong evidenceBisacodyl, sodium picosulfate, or senna stimulates bowel movement.View evidence note

What it is

Common rescue or add-on options, with varying evidence by agent and duration.

Evidence snapshot

Guidelines strongly recommend bisacodyl or sodium picosulfate short term or as rescue and suggest senna.

Safety focus

Cramping and diarrhea can occur. Suspected obstruction, severe pain, bleeding, or unexplained new constipation requires evaluation.

Connected condition

Chronic constipation overview →

Evidence rating reviewed August 2026. Source: AGA/ACG constipation guideline.

Secretagogues and prucaloprideStrong evidenceIncreases intestinal fluid or motility after inadequate OTC response.View evidence note

What it is

Options include linaclotide, plecanatide, lubiprostone, and the 5-HT4 agonist prucalopride.

Evidence snapshot

Guidelines recommend linaclotide, plecanatide, or prucalopride and suggest lubiprostone after OTC failure.

Safety focus

Diarrhea, dehydration, nausea, obstruction, pregnancy, age, kidney function, mood warnings, and product-specific interactions matter.

Connected condition

Chronic constipation overview →

Evidence rating reviewed August 2026. Source: AGA/ACG constipation guideline.

ULT

Prescription medication · Urate lowering2 common approaches

Urate-lowering therapy

Long-term medicine lowers serum urate to dissolve crystals, prevent flares, shrink tophi, and protect joints.

AllopurinolStrong evidenceFirst-line xanthine oxidase inhibition for most people who need urate lowering.View evidence note

What it is

Started low and titrated using serum urate, including in CKD, usually with temporary flare prophylaxis.

Evidence snapshot

ACR strongly recommends allopurinol first line and a treat-to-target strategy below 6 mg/dL for most treated patients.

Safety focus

Rash can signal rare severe hypersensitivity. Kidney function, interactions, dose titration, and HLA-B*58:01 testing in higher-risk ancestry groups matter.

Connected condition

Gout overview →

Evidence rating reviewed August 2026. Source: ACR gout guideline.

Febuxostat or uricosuric therapyStrong evidenceProvides alternatives when allopurinol is ineffective, contraindicated, or not tolerated.View evidence note

What it is

Febuxostat also blocks urate production; probenecid increases kidney urate excretion in suitable patients.

Evidence snapshot

Both lower urate effectively, but selection follows cardiovascular history, kidney function, stones, interactions, and prior response.

Safety focus

Febuxostat cardiovascular warnings, liver monitoring, flare prophylaxis, kidney stones, and multiple drug interactions require review.

Connected condition

Gout overview →

Evidence rating reviewed August 2026. Source: ACR gout guideline.

FL

Prescription anti-inflammatory treatment2 common flare options

Colchicine and glucocorticoids for gout flares

Two first-line alternatives to NSAIDs for rapidly suppressing crystal-driven inflammation.

Low-dose colchicineStrong evidenceDisrupts inflammatory-cell response to urate crystals.View evidence note

What it is

Works best when started early and is also used at lower preventive dosing during urate-lowering initiation.

Evidence snapshot

Low-dose colchicine is as effective as older high-dose regimens with fewer gastrointestinal harms.

Safety focus

Kidney or liver impairment and strong CYP3A4 or P-gp interactions can cause fatal toxicity; diarrhea and muscle injury require attention.

Connected condition

Gout overview →

Evidence rating reviewed August 2026. Source: ACR gout guideline.

Oral or injected glucocorticoidStrong evidenceSuppresses flare inflammation systemically or in the affected joint.View evidence note

What it is

Prednisone or joint injection is useful when NSAIDs or colchicine are unsuitable.

Evidence snapshot

Glucocorticoids are a strongly recommended first-line flare option with comparable pain relief.

Safety focus

Infection must be excluded in a hot joint. Glucose, mood, sleep, blood pressure, fluid retention, and repeated steroid exposure matter.

Connected condition

Gout overview →

Evidence rating reviewed August 2026. Source: ACR gout guideline.

FM

Lifestyle and behavioral treatment2 foundational approaches

Exercise and self-management for fibromyalgia

Gradual movement and skills for pacing, sleep, stress, and pain coping form the foundation of long-term fibromyalgia care.

Regular low-impact exerciseStrong evidenceImproves pain, fatigue, sleep, and function over time.View evidence note

What it is

Aerobic, resistance, aquatic, yoga, or tai chi activity started below the flare threshold and progressed gradually.

Evidence snapshot

Exercise is the most consistently effective fibromyalgia treatment, with modest average benefit across symptoms and function.

Safety focus

Initial soreness is common; boom-and-bust overexertion can trigger flares. New focal neurologic, inflammatory, or cardiopulmonary symptoms need separate evaluation.

Connected condition

Fibromyalgia overview →

Evidence rating reviewed August 2026. Source: ACR fibromyalgia guide.

Education, pacing, sleep care, and CBTModerate evidenceReduces symptom interference and builds sustainable routines.View evidence note

What it is

Self-management combines validation, symptom education, consistent activity, planned recovery, sleep-disorder care, and coping skills.

Evidence snapshot

CBT and multicomponent programs improve coping, mood, and function, although they do not imply symptoms are psychological in origin.

Safety focus

Avoid programs promising a cure or demanding exercise through severe worsening. Screen for sleep apnea, depression, trauma, and medication effects.

Connected condition

Fibromyalgia overview →

Evidence rating reviewed August 2026. Source: ACR fibromyalgia guide.

SNRI

Prescription medication · SNRIFibromyalgiaStrong evidence

Milnacipran

An SNRI approved for fibromyalgia that modifies serotonin and norepinephrine pain pathways.

View evidence note

Open mechanism, evidence, safety, and connected condition

What it is

Milnacipran is titrated gradually and may be considered when pain, fatigue, and function remain limiting despite foundational care.

Evidence snapshot

Controlled trials show modest average symptom benefit, with meaningful response in a subset of patients.

Safety focus

Nausea, sweating, constipation, heart-rate or blood-pressure increase, urinary hesitation, serotonin interactions, mood changes, and gradual tapering require review.

Connected condition

Fibromyalgia overview →

Evidence rating reviewed August 2026. Sources: ACR fibromyalgia guide and FDA prescribing information.

VAR

Prescription medication · Nicotinic partial agonistTobacco dependenceStrong evidence

Varenicline

A non-nicotine medicine that reduces withdrawal and blocks some of nicotine’s rewarding effects.

View evidence note

Open mechanism, evidence, safety, and connected condition

What it is

Usually started before a quit date or with a flexible quit approach and combined with behavioral support.

Evidence snapshot

Varenicline is among the most effective single smoking-cessation medicines.

Safety focus

Nausea, vivid dreams, sleep change, kidney dosing, alcohol effects, pregnancy, and new mood or behavior changes require review.

Connected condition

Tobacco dependence overview →

Evidence rating reviewed August 2026. Source: CDC clinical tobacco-dependence guidance.

NRT

OTC or prescription medication · Nicotine replacementTobacco dependenceStrong evidence

Combination nicotine replacement therapy

A long-acting nicotine patch controls baseline withdrawal while gum or lozenge treats breakthrough cravings.

View evidence note

Open mechanism, evidence, safety, and connected condition

What it is

NRT delivers nicotine without combustion toxins and is adjusted to baseline use and withdrawal.

Evidence snapshot

Combination NRT is more effective than one form alone and works best with behavioral support.

Safety focus

Correct gum technique, skin reactions, nausea, palpitations, recent unstable cardiovascular disease, pregnancy, and safe storage away from children and pets matter.

Connected condition

Tobacco dependence overview →

Evidence rating reviewed August 2026. Source: CDC clinical tobacco-dependence guidance.

BUP

Prescription medication · Bupropion SRTobacco dependenceStrong evidence

Bupropion SR for tobacco dependence

A non-nicotine medicine that reduces craving and withdrawal through norepinephrine and dopamine pathways.

View evidence note

Open mechanism, evidence, safety, and connected condition

What it is

Usually started before the quit date and sometimes combined with nicotine replacement.

Evidence snapshot

Bupropion SR improves long-term quit rates compared with placebo.

Safety focus

Avoid with seizure disorders, certain eating disorders, MAO inhibitors, or abrupt alcohol or sedative withdrawal. Sleep, blood pressure, mood, and duplicate bupropion products require review.

Connected condition

Tobacco dependence overview →

Evidence rating reviewed August 2026. Source: CDC clinical tobacco-dependence guidance.